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Abstract
The Epithelial-to-Mesenchymal transition, a critical cellular process in development, is frequently
co-opted by solid tumors to promote invasion and metastasis. In particular, the hybrid or
intermediate EMT state, possessing both epithelial and mesenchymal characteristics, is
associated with increased cancer stemness and plasticity. Similarly, intra-tumoral heterogeneity
in solid tumors, in particular breast cancer, is associated with poor prognosis, tumor growth,
proliferation, drug resistance, and metastasis. We sought to understand the link between the
generation of intra-tumoral heterogeneity and the intermediate EMT state and their impact on
tumor progression and patient prognosis. As part of my thesis work, I developed a model to
study EMT by isolating single cell-derived clonal populations along the EMT spectrum of cell
states using the SUM149PT basal-like breast cancer cell line and validated the impact of
intermediate EMT states on tumor progression and metastasis in an orthotopic mouse model.
Using this model, I developed and tested a novel multiplexed multi-round staining approach to
identify and quantify E-M heterogeneity and EMT score in breast cancer. These metrics were
further validated with high reproducibility on a large cohort of breast cancer patient samples,
while developing the approach in a high throughput-adaptable way for broad use. This
comprehensive analysis highlighted the impact of high E-M heterogeneity and overall
intermediate EMT scores on decreased overall survival in these patients. Further, we used the
SUM149PT model to understand the driving transcriptional networks of the intermediate EMT
and identified CBFb as a regulator of metastasis in the intermediate state by promoting tumor
heterogeneity and stabilizing the intermediate EMT state. Taken in its totality, this work provides
the further support for understanding intermediate EMT states and their roles in cancer
metastasis and heterogeneity, a framework for comprehensive identification of E-M tumor
heterogeneity in patient samples, and therapeutic targets that can help to reduce the presence
of this tumorigenic and metastasis-promoting phenotype in patients.
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Chapter 1. Introduction
1.1 Overview of the Problem
Metastasis to distant organ sites accounts for 90% of cancer associated deaths from solid
tumors1. This is due to many factors, including difficulty in locating metastatic disease,
resistance to treatment, and heterogeneity amongst metastatic lesions. Understanding the
principles that govern metastasis in solid tumors presents an avenue at all stages of disease
from prevention, location, targeting, and treatment. Much of the metastatic potential of a tumor
seems to be linked to intra-tumoral heterogeneity. This is especially prevalent in triple negative
breast cancer, a subset of breast cancers defined by ER/PR negative staining and no HER2
amplification. A key contributor to both heterogeneity in TNBC and later stage chemo-resistance
and metastasis is the Epithelial-to-Mesenchymal transition (EMT). This normal developmental
program is frequently exploited in the context of cancer to increase migratory abilities,
invasiveness, metastatic potential, and resistance to chemotherapy and has been linked to poor
prognosis in breast2, prostate3, and pancreatic4 cancers.
1.2. Breast Cancer
Breast cancer is a heterogeneous disease that arises in cells of the mammary gland and
exhibits a wide spectrum of morphological, histopathological, and immunohistochemical profiles
that each have unique courses of treatment and outcomes5. Breast cancer is a leading cause
of death in women, accounting for nearly one-quarter of all malignancies in females worldwide.
Adenocarcinomas make up the majority of breast malignancies and is divided nearly equally
into the less aggressive Ductal Carcinoma In Situ (DCIS) and the more aggressive Invasive
Ductal Carcinoma (IDC), although DCIS may progress to IDC at later stages6. While
classification has been challenging, it is broadly classified into either histological or molecular
subtypes based on expression of estrogen (ER) and progesterone (PR) receptors, amplification
of HER2, and Ki67+ staining. Histological classifications are wide-ranging, and predominantly
focus on the morphological features and differentiation state of the tumors. Therapeutically,
breast tumors are pathologically classified into Estrogen driven (ER/PR expressing), HER2
driven (HER2 overexpressing), and Triple Negative (TN, ER/PR/HER2 negative). Molecular
classifications are more concrete, encompassing Luminal A – ER/PR positive and HER2
negative; Luminal B – ER/PR positive, HER2 positive or negative, and Ki67 > 14%; HER2
overexpression – HER2 strong positive, ER/PR variable; and Basal-like – CK5/6 or EGFR
positive, ER/PR negative, HER2 negative, and high Ki67 and TP53 expression5. Generally,
luminal-derived breast cancers are less aggressive and have targeted therapies that rely on the
estrogen and progesterone receptors or HER2, while triple negative or basal like breast cancer

-1-

has very few targeted therapies. Recent evidence has shown that breast cancer cells may
exhibit luminal to basal plasticity which may be responsible for cellular heterogeneity and overall
poorer prognosis7,8. This further strengthens the need to understand plasticity in the context of
cancer.
1.2.1 Triple Negative Breast Cancer (TNBC)
Triple Negative Breast Cancer (TNBC) is characterized most succinctly by ER/PR/HER2
negative staining by immunohistochemistry. The triple negative histological subtype and basallike molecular subtype share many defining features and therefore overlap significantly,
although not completely9. Basal-like can be more homogeneous and is further stratified by
molecular features such as Ki67 and TP53 expression. Regardless, these subtypes are typified
by poor clinical prognosis due to a high incidence of relapse and metastasis10,11. Generally, this
non-estrogen driven class of breast cancer is a catch-all for a heterogeneous array of hormone
negative diseases whose standard-of-care, neoadjuvant chemotherapy and surgery, has
remained largely unchanged. While this therapeutic approach is successful at early stages, with
a pathologic complete response (pCR) rate of 30-40%, if metastasis occurs, the five-year
survival rate drops to less than 30%1. Much of the disease potential and aggressive nature of
this subtype derives from inter- and intra-tumoral heterogeneity, which makes developing
targeted therapies challenging.
1.2.2 Intra-tumoral heterogeneity
There are many contributing factors to the generation of intra-tumoral heterogeneity12. Some
may be genetic, while others may be epigenetic. However, it has been widely understood that
heterogeneity leads to overall poor prognosis and is advantageous for tumor growth,
proliferation, drug resistance, and metastasis13,14. Generation and maintenance of tumor
heterogeneity or diversity is best understood through the lens of evolution. Those adaptations
that are advantageous to the success of the community (i.e. the tumor) are maintained and
expanded, creating a “multi-task”15 ecological paradigm where each subtype of cell has a
defined role to support the community16. Reservoirs of genetic14,17–20 and epigenetic21–24
subclonal diversity have been found in breast cancer many times over25 and are correlated with
overall poorer prognosis in patients. However, a recent study from Navin and colleagues found
that chemoresistance evolution in breast cancer relies predominantly on epigenetic plasticity
rather than genetic diversity to evade treatment26. Thus, understanding the roots of epigenetic
intra-tumoral heterogeneity and cellular plasticity and how this may contribute to metastasis in
breast cancer is critical to overcoming chemoresistance, relapse, and mortality in these patients.
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1.2.3 Therapy approaches
Breast cancer treatment standard of care involves multiple steps to first determine the extent of
disease, including diagnostic imaging, biopsy, and determination of histological and molecular
subtypes27. Hormone positive breast cancers such as Luminal A and B can rely on estrogenderived therapy approaches to target cancer cells, while HER2 enriched subtypes can be
treated with HER2 inhibitors. However, triple negative has no such molecular targets and
mainstay of treatment for this subtype has remained neoadjuvant chemotherapy and resection
since the 1990s. For most early stage, neoadjuvant chemotherapy and surgical resection
followed by adjuvant chemotherapy or radiation is sufficient to prevent the spread of disease
with a pathologic complete response (pCR) rate of 30-40%, however, if metastasis occurs, the
five-year survival rate drops to less than 30%10.
Currently, stage IV metastatic disease is considered incurable and is treated with
systemic chemotherapy alone with no targeted radiotherapy or other molecular therapies27. This
creates a need for further understanding into the metastatic process that may shed light on new
therapeutics that can disrupt metastasizing cells and or specifically target metastatic sites in
triple negative breast cancer.
1.2.4 Metastatic sites
Triple negative breast cancer metastasizes to multiple organ sites and can vary from individual
to individual. In fact, compared to other subtypes, women with triple negative breast cancer
have 2.3 increased likelihood of distance recurrence and death28. Typically, the first site of local
metastasis occurs in the auxiliary lymph nodes and chest wall, while distant metastasis can
occur in the brain, bone, pleural effusion, lung, liver, or a combination of sites11. Depending on
the site, patients had varying outcomes; those with lung metastases faired best while those with
bone, liver, pleura, and brain had increasingly worse median overall survival11. Regardless,
patients bearing metastatic lesions at any site fared worse than those without.
1.3. EMT
The Epithelial-to-Mesenchymal Transition (EMT) was first identified in development as a
mechanism for gastrulation29, neural crest differentiation30, and wound healing31 in mature
organisms. It is also frequently coopted by cancer cells to increase migratory characteristics and
cellular plasticity to aid in tumor invasion, metastasis32,33, and chemoresistance34,35 and is a key
contributor to intra-tumoral heterogeneity36–38. EMT, and its reversal, the Mesenchymal-toEpithelial transition (MET), is a non-genetically driven phenotypic switch between an epithelial
and mesenchymal cell state34,39.
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While embryonic development generates a diverse array of cell types, they can most
generally be categorized by two-dimensional organization with their neighbors (epithelial) or
three-dimensional organization with their neighbors (mesenchymal). Mesenchymal cells are
irregular and difficult to define and have generally been categorized by being non-epithelial40,41.
The characteristics of an epithelium are as follows: “A two-dimensional epithelial structure is
generally marked by the presence of (i) apico-basal polarity; (ii) a transepithelial barrier (tight
junctions or septate junctions); (iii) an epithelial specific cell–cell adhesion mediated by
adherens junctions; and (iv) a basement membrane-like extracellular matrix”42. On the other
side, mesenchymal cells are generally characterized having lost those cell-cell junctions and, as
a result, gain increased motile and invasive characteristics through formation of actin-based
protrusions called lamellipodia and filopodia that mediate cell migration43 (Figure 1).
This conversion of epithelial cells to a migratory and invasive phenotype was first seen in
3D collagen gels29, the first indication that these cell states were much more plastic than
previously believed. During an EMT, cell-cell adhesion mediated by tight and adherens junctions
and cell-extracellular matrix interactions are downregulated remodeled, leading to a detachment
of cells from one another and the underlying basement membrane. Simultaneously,
mesenchymal transcriptional programs are upregulated which promote actin remodeling and
production of intermediate filaments and integrins which aid in extracellular matrix remodeling to
promote invasion and migration33,44. Morphologically, cells lose a cobblestone-like morphology
and gain spindle-like mesenchymal traits. However, recent evidence has shown that this is not
just a binary transition from epithelial to mesenchymal state, but rather exists as a spectrum of
phenotypes including intermediate or partial EMT states that co-express to varying degrees both
epithelial and mesenchymal cell characteristics45–51. These transition states possess unique
characteristics45,46,52,53 and contribute to gastrulation54, wound healing55, and tumor
heterogeneity and metastatic behavior8,56.
These dynamic changes in characteristics of epithelial cells allow these cells to respond
to the changing cellular demands during embryonic development and wound closure, as well as
those demanded by the metastatic cascade in cancer.
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Figure 1: A diagram of the cellular spectrum of EMT, including genes expressed in various
cell states along the spectrum. Crea
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1.3.1 EMT Circuitry
Much work over the last 20+ years has contributed to our understanding of the transcriptional
networks and extracellular signaling that initiate, drive, and stabilize the epithelial-tomesenchymal spectrum of cell states. These cellular changes were found to be driven by
decreases in cell-cell interactions, modulated by E-cadherin and N-cadherin, and increases cellsubstrate interactions regulated by extracellular matrix (ECM) proteins like fibronectin and
integrins57–59. Experiments in sea urchin further revealed the complexity of EMT and its role
in basement membrane remodeling, motility, apical constriction, loss of apicobasal polarity, and
changes in intercellular adhesion, all critical functions during gastrulation. Interestingly, this
analysis revealed thirteen core transcription factors, although no single TF was present in all
five sub-circuits indicating a robust and potentially redundant network60. However, these
transcriptional cascades must be started by a signal.
1.3.1a Extracellular Signaling
TGFb, WNT, Notch, and FGF signaling have all been shown to work in context-dependent ways
to activate EMT via EMT-promoting transcription factors. These pathways and their interactions
with one another are complex and have been reviewed extensively33,35,61 (Figure 2).
Transforming growth factor beta (TGFb), the most common and well-studied, was first
identified in cell culture to promote an EMT in epithelial cells and increase expression of
fibronectin and vimentin62. Extracellular signaling by TGFb at the TGFbR1 and R2 receptors
leads to the phosphorylation of SMAD2 and SMAD3, which go on to complex with SMAD4.
Similarly, SMAD1 and SMAD5 are activated by TGFb via bone morphogenic proteins (BMPs),
which also complex with SMAD4. These complexes then translocate to the nucleus and function
as transcription factors driving the expression of a large network of genes that drive the
mesenchymal state, in particular, members of the Snail, ZEB, and Twist families of transcription
factors61.
The canonical WNT pathway is considered to be a key activator of EMT in neural crest
formation63 and wound healing64. WNT acts through the Frizzled receptor to release b-catenin
into the nucleus to activate target genes involved in cell differentiation among others61.
NOTCH signaling primarily regulates cell fate decisions, differentiation, and proliferation,
similarly to WNT33. The NOTCH intracellular domain (NOTCH-ICD) is cleaved upon extracellular
signaling from Delta or Jagged, where it translocates into the nucleus driving expression of its
target genes65.
Fibroblast growth factor (FGF) and epidermal growth factor (EGF) have been shown to
induce an EMT via Ras/MAPK and PI3K-AKT pathways by upregulating Snail expression66.
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These pathways do not act alone. TGFb -SMAD also interacts with b-catenin, NOTCH-ICD, as
well as the Ras and PI3K-AKT pathways to centralize signaling and activate and coordinate
signals across pathways to upregulate EMT networks33.
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Figure 2. A diagram of extracellular inputs and EMT regulatory circuitry. Created with
Biorender
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1.3.1b EMT transcriptional networks
Extracellular signaling activates a core EMT transcriptional network that goes on to repress
epithelial genes, activate mesenchymal genes, and regulate one another through either direct or
indirect (micro-RNA) transcriptional regulation. Our understanding of this network comes from a
large body of literature35,43,61,67–69 on both the role of EMT in developmental processes and EMT
in cancer.
The transcriptional network of epithelial and mesenchymal genes is orchestrated by the
Snail (Snail & Slug)70, ZEB (ZEB1 & ZEB2)71, bHLH (TWIST1 & TWIST2)72,73, and PRRX174
families, all of which have been shown to be strong EMT drivers in culture and in vitro.
Transcriptional regulators that are unique to specific EMT states have recently been identified to
expand upon this core unit46,75. These transcription factors have many targets but they
predominantly function as repressors of epithelial genes such as E-cadherin and claudins,
occludins, desmosomal components that stabilize and makeup apical adherens juncitons48.
Additionally, these EMT TFs activate mesenchymal genes such as fibronectin, vimentin, Ncadherin, and MMPs which facilitate motility and invasion through extracellular matrix76. At the
core of this regulatory unit is a feedback loop between Snail and ZEB177, which activate one
another, and their repressive micro-RNAs, miR-3478 and miR-20079,80, respectively69.
The Snail family, Snail (SNAI1) and Slug (SNAI2), are the first discovered and first
activated transcription factor in this transcriptional network, responding to TGFb81, WNT, Notch,
and FGF (MAPK and NF-kb) pathways82. It acts directly on the E-cadherin promoter to repress
expression of E-cadherin83 as well as directly activating the promoter of ZEB184. Further, Snail
recruits histone deacetylases (HDACs)85 and methylases86 to the E-cadherin promoter,
promoting a bivalent poised chromatin state that may be responsible for plasticity during both
embryonic development and cancer87,88.
ZEB1 also acts as a repressor of E-cadherin61 and other epithelial-related genes89
through recruitment of the SWI/SNF chromatin remodeling complex90. ZEB1 is activated by
TGFb, WNT, and the MAPK pathways43. As with Snail, ZEB1 is able to recruit HDACs to the
promoter of E-cadherin, although it appears this is primarily to permanently suppress epithelial
genes91. In this way, the Snail-ZEB1 axis serves as a reversible and then subsequently (semi-)
irreversible switch as EMT signaling progresses77. However, ZEB1 also acts to inhibit OVOL2,
an epithelial state-promoting transcription factor92,93, to maintain feedback between epithelial
and mesenchymal states to promote plasticity94. Further, the ZEB1 promoter itself was
discovered to maintain a bivalent chromatin configuration, awaiting signaling from TGFb to enter
a highly plastic, stem cell-like state that enhances tumorigenicity in breast cancer95.
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TWIST1, a member of the bHLH TF family including TWIST2, acts in a similar, albeit
independent manner to Snail, both repressing E-cadherin and inducing N-cadherin in
combination with other proteins96,97. It is activated by the MAPK pathway98 and works
cooperatively with Snail to upregulate ZEB1, strengthening this EMT-inducing circuit84.
PRRX1, a transcriptional driver of EMT99, is stimulated by the TGFb and WNT pathways
and, like other canonical EMT-TFs, represses E-cadherin and activates expression of
Vimentin74,100.
The RUNX transcriptional family is a more recently identified group of transcription
factors separate from the core drivers, that regulate proliferation, migration and invasiveness in
cancer101 as well as in developmental processes that frequently overlap with EMT102. It consists
of sister proteins RUNX1, RUNX2, RUNX3, which all interact individually with their co-activator
CBFb via the runt domain103. Each RUNX protein has specific functions and tissue
expression104, although they may act as redundant paralogs in some cases. RUNX2 in particular
as been associated with mammary development105 and luminal progenitor cells, suggesting a
role in mammary stem cell regeneration driven by WNT signaling106 as well as the maintenance
of breast cancer stem cells107. Coactivator CBFb itself has also been shown to have a role in
maintaining a metastatic phenotype in breast cancer through regulation of EMT transcription
factors such as Slug108. Further, the runt domain through which all three RUNX TFs interact with
CBFb has shown promise as a molecular target to disrupt the interaction and activation of these
RUNX TFs, creating a potential targetable mechanism to disrupt the function of the entire RUNX
family109.
1.3.2 EMT In Development
1.3.2a Gastrulation and neural crest migration
Gastrulation, or the formation of the gut, is generally regarded as the earliest and most typical
EMT event in animal development42. This process gives rise to the ectoderm, mesoderm, and in
triploblast or metazoan kingdom, endoderm. The pre-gastrulation blastula cells are generally
characterized as epithelial and undergo an EMT to generate the mesoderm and ectoderm. This
program was found to be induced by signal cooperation between WNT, FGF and TGFb
families110 and orchestrated by transcription factors Twist and Snail in Drosophila111 where Snail
controls the switch of E-cadherin to N-cadherin112
Neural epithelial cells undergo EMT to migrate during the formation of the neural crest
and form distal parts of the central nervous system (CNS) following induction in the ectodermal
layer post-gastrulation30. This is a tightly regulated mechanism requiring a network of multiple
feedback loops to generate robust development of the neural crest induced by FGF, WNT,
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Notch, and BMPs113, leading to poised chromatin states at the Snail promoter amongst many
other EMT-related genes114.
1.3.2b Wound healing
Outside of development, motility is generally a characteristic of certain pathologies and not part
of normal epithelial cell function. The exception being in wound healing, which activates cellular
plasticity in multiple cell lineages as a repair response to damaged tissue31. This is a critical use
of EMT in a normal context, but also gives insight into how EMT may be activated in a variety of
tissue types in a pathological background such as cancer. After trauma from injury, epithelial
cells at the wound edge undergo a partial EMT to be able to collectively move as a coordinated
group, requiring cell-cell junctions of the epithelial state as well as mesenchymal motility, and
tightly regulated by Slug (Snail2)55. MET inducing transcription factors such as GRHL1/2/3 are
responsible for the careful regulation and return to a fully epithelial state115,116.
1.3.3 EMT In Cancer
EMT and its reversal, MET, are critical components of the metastatic cascade in breast cancer
and many other solid tumor types67,117–120. This embryonic developmental program increases
invasive and migratory behavior that is advantageous to a metastasizing cancer cell34, enabling
them to disseminate to distant organs. Indeed, patients whose tumors express high levels of
EMT signatures have worse overall prognoses and increased rates of metastasis121,122. In the
context of cancer, EMT may be activated by a variety of factors, including master EMT regulator
TFs, such as Snail83, Twist1/272, ZEB1123,124, and PRRX199, detailed in 3.1 EMT circuitry.
However, most often, EMT is induced by TGFb signaling from stromal cells surrounding the
primary tumor site. These stromal cells, made up of fibroblasts, myofibroblasts, endothelial,
myeloid, and lymphoid cells, over the course of tumor progression, begin to resemble stroma
surrounding an epithelial wound, and begin to release signals as such119. Upon induction, EMT
networks progress in a similar fashion to those seen in development and wound healing, via
upregulation of Snail leading to repression of E-cadherin and activation of other EMT TFs and
mesenchymal genes. These tumor cells gain migratory characteristics that allow them to invade
the surrounding stroma either as mesenchymal single cells, or as clusters of cells that may
express a range of epithelial and mesenchymal characteristics119.
Particularly, plasticity within this transition, including its reversal to regain epithelial and
proliferative characteristics, has been demonstrated in metastatic colonization100,125. The plastic
nature of the metastatic cascade further elaborates the utility of an intermediate or partial EMT
state where cells co-express both epithelial and mesenchymal markers.
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Previous works questioned the relevance of EMT in metastasis in breast126 and
pancreatic127 cancers, however these conclusions were based in either incomplete disruption of
the intermediate EMT128 or in lineage markers related to a highly mesenchymal state129,130.
1.3.3a Intermediate EMT - plasticity and stemness
Rather than being a switch from an epithelial to a mesenchymal state, increasing evidence
points to the existence of intermediate or partial EMT states, wherein cells co-express both
epithelial and mesenchymal traits45–51. This is advantageous not only in wound healing and
development, where transition back and forth between epithelial and mesenchymal – or E-M
plasticity (EMP) – is necessary, but also in cancer. These robust stable and metastable
transition states possess unique characteristics45,46,52,53 and contribute to the complex
heterogeneity of tumors and their overall metastatic behavior8,56. The intermediate EMT state
has been enigmatic to study for some time130. It is transient, can be problematic to demarcate
between systems131, and has proven complicated to track through many lineage tracing
efforts126,130,132,133. However, its importance in cancer is well defined, as is its association with
stem-like characteristics49–53. This unique behavior manifests itself in a multitude of ways,
contributing to tumor heterogeneity, tumor initiating ability, and collective cell migration, but is
best summed up by the term “plasticity”.
Cellular plasticity can be difficult to define, and even more complicated to measure.
Evolutionarily, it may be thought of as fitness, or adaptability15. In the context of EMT, plasticity
or cellular stemness may refer to the ability of cells to interconvert between E and M-like states
rapidly and with ease. However, it may also be the case that co-expression of E and M genes
negates the need to interconvert between the states, but rather exist as a stem-like population,
prepared for anything. Whether intermediate states are simply poised, ready for rapid switches
between states, or are in themselves the highest fitness state is not known. Nevertheless, the
utility of plasticity in the demanding environment of the metastatic cascade is clear. Cells of
highly epithelial or mesenchymal origin have both decreased plasticity, as measured by tumorinitiating ability, and decreased metastatic capabilities100,125.
While much work has been carried out identifying and characterizing EMT-inducing
transcription factors70,71,73,134, the transcriptional and epigenetic networks responsible for the
stability and maintenance of the midpoints along the EMT spectrum are poorly defined.
Additionally, multiple partial or intermediate states ranging from early- to late-intermediate have
been defined. Efforts to elucidate these networks as well as the diversity of intermediate EMT
states in recent years range from treatment timecourses135, population isolation46, and lineage
tracing136.
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1.3.3b EMT tumor heterogeneity
One of the hallmark contributing factors to poor prognosis as a result of EMT is linked to its
ability to generate high levels of intra-tumoral heterogeneity, or the extent of cellular diversity
within a tumor. As discussed above (1.2.2 Intra-tumoral heterogeneity), tumor heterogeneity,
from both genetic and epigenetic sources, is correlated with overall poorer survival in a variety
of tumor contexts. The individual cell activation of EMT from the exterior to the interior of the
tumor produces a wide variety of cell states within that tumor at any given time. Cells on the
periphery tend to have more mesenchymal features as they are closest to the extracellular
stimuli produced by the surrounding stroma137, and the tumor therefore has a gradient of
phenotypes from mesenchymal to epithelial from the exterior to the interior138,139. This gradient
may change as the tumor grows and signaling from the stroma fluctuates based on a general
“inflammation phenotype” 119,137. This architecture, of course, gets more complicated when
considering stroma within the tumor, but a radiant signal approach is often the best way to
describe activation of EMT within a tumor. However, a continuous exposure to EMT-inducing
stimuli would theoretically lead to a fully mesenchymal tumor over time; this is not the case.
Maintenance of a heterogeneous population of tumor cells is advantageous to the fitness
landscape of the tumor acting as a community, otherwise known as “multi-task”15,16 ecological
paradigm. Therefore there must be regulatory networks that control the maintenance and
stability of the intermediate EMT state, which is both the most metastatic and stem-like
phenotype, and therefore likely to be maintained by a tumor community140. Indeed, the NotchJagged pathway, as well as other ‘phenotypic stability factors’141 play an important role in both
the stability and promotion of intermediate EMT state(s) as well as cancer stem cell (CSC)
populations in breast cancer137. However, the stability and metastability of EMT states within the
tumor at a static point or as a dynamical system is still not well understood. Further, the role that
cellular plasticity plays in maintaining a stem-like or intermediate EMT population, or indeed the
percentage of cells required at any given time, is also muddied.
Understanding that tumor heterogeneity generated by EMT is correlated with poor
prognosis has been well explored, as has attempts to quantify, track, and understand this
heterogeneity. Single-cell based methods of quantifying tumor heterogeneity, both genetically
and transcriptionally, have also been successful and contributed to our understanding of tumor
heterogeneity in models and patients. These topics will be covered in the following section – 4.
Methods of quantifying EMT.
1.3.3c EMT in metastasis
Metastatic disease occurs when cells within the primary tumor gain motile and invasive
characteristics that allow them to invade beyond the borders of the primary site and reach blood
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capillaries. There, cells can be carried within the bloodstream to distant organs where these
tumor cells can then seed a new tumor. Cells must overcome a gauntlet of environmental and
immune pressures and emerge proliferative and intact. EMT, particularly the intermediate EMT
state allow cells to overcome this barrage of environmental pressures by acting as a unit, or a
circulating tumor cluster142. By possessing both epithelial and mesenchymal characteristics,
cells can maintain an invasive mesenchymal edge while still keeping cell-cell junctions to allow
them to travel as a group35. This phenomenon, while rare, has a 50-fold higher metastatic
incidence than single circulating tumor cells alone142. Circulating tumor cells and clusters and
their usefulness as a diagnostic tool are addressed in later sections. Further, there is evidence
that EMT may be occurring in pre-malignant cancers, particularly at sites of inflammation4,
leading to early metastatic dissemination, as has been seen in breast cancer143,144.
Initially, cells were thought to regain epithelial characteristics upon seeding a new
125,145

tumor

. However, it may be the case that intermediate states maintain the plasticity required

to proliferate at a distant site without regaining epithelial characteristics35,146. Recently, strong
ZEB1 staining was seen in metastases in a lung adenocarcinoma model, indicating that full
reversion to an epithelial state may not be required during metastatic colonization147.
1.4. Methods of quantifying EMT
Adapted from Brown et. al. Cancers 2022131
Critical to our understanding of epithelial-mesenchymal Plasticity (EMP) and its underlying
regulators is our ability to distinguish unique EMT states from one another for identification in
vitro, in vivo, and in patient samples. EMP and heterogeneity have frequently been associated
with poor patient outcomes121,122, however, no robust method for assessing either of these has
been developed to complement histopathological assessment in the clinic setting. The presence
and role of a variety of hybrid EMT states in disease progression and metastasis remains a
lynchpin in EMT-based therapies. Current evidence suggests that rather than relying solely on
an MET to revert from a fully mesenchymal state, metastasis may result from the high plasticity
and adaptability of the intermediate or hybrid states38, as seen by the presence of intermediate
circulating tumor cell clusters (CTCs clusters)142,148. Regardless of a clear-cut mechanism, which
is still currently in debate, the presence of an intermediate state appears to be critical to the
formation of metastasis, either through plasticity or as a transitional state.
Various methods that have been utilized to identify the spectrum of E-M states within a
sample, from flow cytometry to single-cell analysis of the intricate RNA and protein expression
patterns found in mouse and human tumors. Ultimately, one or a combination of these methods
could be applied to assess patient prognosis by providing rapid and comprehensive analysis of
EMT state and heterogeneity of tumors to inform disease aggression and treatment regimens.
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1.4.1 Epithelial And Mesenchymal Markers
Several markers have been used over the years, firstly to determine the occurrence of EMT
and, more recently, to distinguish various distinct states along the epithelial-to-mesenchymal
spectrum. These markers are based on a range of properties from those that inform stemness,
to those that indicate morphological changes, and transcriptional regulators (EMT and MET
TFs) of the transition. These markers have been used in various combinations, each with their
own benefits and deficits, based on context, specificity, and ease of use.
1.4.1a Morphological Markers of EMT
The first discovered and readily utilized markers for EMT relate directly to the morphological
changes that cells undergo to enhance invasion and motility, such as loss of classical epithelial
adherens tight junction proteins, and gain of non-canonical alternative intermediate filaments. Ecadherin, a key component of adherens junctions, was first identified as lost in epithelial cells
that gained invasive characteristics149. Other adherens and tight junctional components that are
key indicators of the epithelial state include claudins, occludins, and catenins as well as
desmosomal components such as desmoglein and desmocollin48. On the other hand, markers
such as Vimentin150,151, fibronectin, N-cadherin, and smooth muscle actin (SMA)152 have all
been used to identify mesenchymal-like cells as invasion and/or progression markers in multiple
cancer types. Co-expression of one or more epithelial markers along with mesenchymal
markers e.g. E-cadherin and Vimentin, is frequently used to identify intermediate or hybrid EMT
states153.
1.4.1b Cell Surface Markers
While epithelial and mesenchymal markers such as E-cadherin, Vimentin, and Fibronectin serve
to describe the internal cellular processes of EMT, they can be difficult to identify without
permeabilization of the cell membrane, given their predominant intracellular localization.
Consequently, cell surface markers and receptors have been adopted to identify and isolate EM states while maintaining cell viability. EMT states were first stratified by CD44 and CD24154,
and later by CD104 (ITGB4)52, to identify tumorigenic populations of cells, linking the invasive
and disease progressing nature of EMT to stem-like processes of cancer stem cells, particularly
in breast cancer49,50. EpCAM, an epithelial cell adhesion molecule similar to E-cadherin, has
been used in many ways to identify cells exhibiting an epithelial state, particularly CTCs155 and
as a marker for flow cytometry156. Notably, Pastushenko et. al46 profiled a panel of cell surface
markers to describe the transitions across an EMT, identifying a gating strategy using Epcam,
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CD106, CD51, and CD61 that accurately captured cells in an intermediate state. These will be
discussed in more detail below.
1.4.1c Transcription Factors
In addition to morphological characteristics, gene regulators of EMT or MET such as
transcription factors provide a finer metric for measuring the progression of a cell across
epithelial and mesenchymal transitions, and have been reviewed extensively157. These markers
provide specificity, particularly when paired with morphological features. Master EMT regulator
TFs, such as Snail, Twist1/2, ZEB1, and PRRX1, detailed in 3.1 EMT circuitry, were originally
identified as repressors of E-cadherin and regulators of plasticity and EMT. Conversely,
OVOL1/2 are required for suppression of EMT and induction of MET in breast158 and skin159
epithelial and cancer92. These markers, as well as others detailed in other reviews157 have been
used extensively in transcriptomics-based approaches to rank EMT160 as well as image-based
methods, described later.
While several other cytoskeletal proteins such as FSP1161 and aSMA162, secreted
proteins including fibronectin96 and MMPs163 and epithelial junctional proteins such as claudins
and occludins164 have been employed as EMT markers in different contexts, these have not
specifically been used to identify intermediate/hybrid EMT states and could possibly highlight
cells that reside in more extreme epithelial or mesenchymal states.
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Table 1: A summary of key EMT marker proteins and their use and relevance in
determining EMT state
Marker
E-cadherin
EpCAM
Vimentin

CD44/CD24
CD106/CD5
1/CD61
CD104
(ITGb4)
Snail

Twist
ZEB1

PRRX1

OVOL1/2

Method(s)
IF, transcriptional
EMT scores,
Flow Cytometry,
Circulating tumor
cells
Intracellular Flow
cytometry, IF,
transcriptional EMT
scores
Flow Cytometry
Flow Cytometry
Flow Cytometry

Importance
One of the first epithelial markers.
Used for many analysis methods
Epithelial marker used in flow
cytometry and CTC detection.
Frequently lost early in EMT
Mesenchymal marker used in many
analysis methods
Stemness markers first used to
separate epithelial and mesenchymal
states
Used to segregate multiple EMT
states
An improved marker to replace CD24

Source(s)
Behrens
1989149
Riethdorf
2007155
Schnell 2013156
Sommers
1991150
Thompson
1992151
Al-Hajj 2003154
Pastushenko
201846
Bierie 201752

IF, Transcriptional
methods,
multiplexed image
analysis
IF, Transcriptional
methods

Transcriptional repressor of Ecadherin, responds to TGFb signaling.

Cano 200083
van Staalduinen
2018157

Hallmark EMT transcription factor

IF, Transcriptional
methods,
multiplexed image
analysis
IF, Transcriptional
methods

Hallmark EMT-driving transcription
factor, repressor of E-cadherin

Transcriptional
Methods

MET transcription factor responsible
for maintaining and epithelial state

Yang 200472
van Staalduinen
2018157
Guaita 2002123
Eger 2005124
van Staalduinen
2018157
Takahashi
201399
Hardin 2014165
Guo 201574
Roca 201392
Watanabe
2014158
Li 2014159
van Staalduinen
2018157

EMT transcription factor prevalent in
late EMT
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1.4.2 Model Systems Used To Study EMP
1.4.2a Cell lines
Immortalized or cancer derived cell lines have been used for decades as models to understand
cancer at a basic level. They are easy to work with, highly manipulable, and can provide a basis
for testing novel drugs and therapies. Cell lines have been used to perfect many of the methods
detailed below, including flow cytometry, immunofluorescence, and RNA-sequencing.
Databases such as the cancer cell line encyclopedia (CCLE) and ATCC serve as repositories
for data and frozen stocks of cell lines for research use. However, cell lines alone cannot
recapitulate the complexities of an in vivo system, which can be achieved through orthotopic
transplantation in mice, rats, and other model organisms. This model, therefore, serves as a
necessary but simple steppingstone to understanding E-M heterogeneity and plasticity in
patients.
1.4.2b Genetically engineered models
In efforts to recapitulate EMT in human disease for laboratory study, many different non-human
models have been generated that mimic aspects of patient disease to study the roles of EMT
and MET in tumor development, progression, and metastasis. Most popular are genetically
engineered mouse models (GEMMs), although zebrafish166,167, drosophila168,169, and sea
urchin170,171 models have been elegantly used to generate important insights in the field. These
GEMMs provide an excellent framework for studying the metastatic cascade, allowing for
spontaneous tumorigenesis in a specific tissue of choice, collection of organs and circulating
tumor cells for basic research and diagnostic development, and testing novel drug targets in a
complex living system. GEMMs have been used with great success to isolate and study EMP in
vivo in breast46, skin46, pancreatic71, and prostate172 cancer. Additionally, immune compromised
mouse models can host human derived cell lines or patient derived xenografts, which, when
transplanted orthotopically into the tissue of origin, can recapitulate the nuanced disease of that
individual for further study.
Overall, mouse and other models of human cancer have been crucial in expanding on in
vivo dynamics of the metastatic cascade where cell lines have fallen short.
1.4.2c Primary Human Tissue
Ultimately, the best tool for studying human disease is directly on human patient samples. This
can be tumor or tissue biopsies either taken fresh or stored in a formalin fixative, as well as
circulating tumor cells, cytological specimens, secondary site biopsies etc. However, acquiring
patient samples and full patient data can be challenging and take years. Databases such as The

- 18 -

Cancer Genome Atlas (TCGA) contain complete sequenced genomes for thousands of primary
patient samples and can be a helpful bioinformatic tool to begin transitioning from basic to
translational research such as validating cancer predictor genes or looking for large trends
across many samples. EMP has been successfully identified, validated, and explored in patient
cancers, including in circulating tumor cells122,173,174, determining EMT gene signatures in
primary tissue175,176, and mapping EMT states at single cell resolution177,178, both substantiating
its relevance in patient disease and opening new possibilities for diagnostic approaches.
1.4.2d Circulating Tumor Cells
Circulating tumor cells in the blood have served as a “window to cancer” for many years179,180.
As a diagnostic tool, it is easy to implement on patients, requiring only a small blood sample,
and can be used to screen tumor cells in a multitude of ways181, including
immunofluorescence173, RNA in situ hybridization (ISH)148, and RNA-sequencing142. CTC
collection methods have also helped to validate the significance of an EMT in the metastatic
cascade148,173, as well as a possible requirement for the reversal, or MET, to colonize metastatic
organs145.
Traditionally, circulating tumor cells were harvested using the cell surface marker
EpCAM155, as most cancers of interest were epithelial in origin. However, EpCAM is lost during
an EMT182 leading to a misrepresentation of CTCs collected by this method. Indeed, even when
captured with an EpCAM retrieval method, CTCs in breast and prostate cancer patients were
found to co-express epithelial and mesenchymal markers in progressive disease121, bringing up
the question of how many EpCAM-negative mesenchymal cells were missed in the analysis. In
response, other microfluidics-based methods of CTC capture have been adopted183,184, although
EpCAM-based methods still dominate patient diagnostics185. Non-specific capture methods
have identified relatively equal populations of epithelial, intermediate, and mesenchymal CTCs,
defined by EMT markers such as E-cadherin and vimentin, however, multiple studies have
found a correlation between high presence of mesenchymal CTCs and worsened patient
prognosis122,145. Along with CTCs, microfluidics devices have also identified circulating tumor
cell clusters (CTC clusters) which, although rare, are much more potent metastatic seeders than
individual CTCs alone142. Under unbiased collection, identification and classification of CTCs
and CTC clusters by microfluidics is a powerful diagnostic tool that can be combined with a
multitude of other methods to understand EMP and its role in the metastatic cascade.
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1.4.3 Methods
1.4.3a FLOW cytometry
Flow cytometry techniques can easily and readily detect cell populations expressing a
combination of cell surface markers. Further, live cell populations can be sorted based on
marker expression via Fluorescence Assisted Cell Sorting (FACS) for further study. This has
made flow cytometry a very popular and easily applicable resource in many early studies
defining E-M states. The invasive nature of cells undergoing an EMT elicited a natural link to
cancer stem-cell like states, prompting these tumorigenic populations of cells to be initially
isolated and described as CD44hi/CD24lo154, ALDH+186 stem-like populations and later linked to
the EMT process49,50. Flow cytometry has provided a means of differentiating Epithelial
(EpCAM+/CD24hi/CD44-) and Mesenchymal (EpCAM-/CD44hi/CD24-) in multiple cancer cell
lines51,187 as well as breast188 and prostate172 mouse model to delineate differences between
these states, understand the unique mechanisms that control EMT and MET, and determine
their various roles in disease progression and the metastatic cascade. Further endeavors to
increase flow sorting sensitivity of E-M states has led to the discovery of novel EMT cell surface
markers such as CD104 (ITGB4)52 as a supplement in addition to CD44/CD24 to define
intermediate EMT states with cancer stem cells properties within human tumors, as well as
combinations of EpCAM, CD51, CD61, and CD10646 to isolate multiple transitional
intermediate/hybrid EMT states from mouse tumor models (Figure 3).
These works and the application of flow cytometry established a link between the hybrid
or intermediate state and increased stemness and decreased patient prognosis using several
cell surface markers, however, this technique is unable to consider the expression of
intracellular markers such as Vimentin or ZEB1, which require cell permeabilization. In addition,
this technique can only be used in live tissue, making it more challenging to study patient
samples, which are often archival formalin fixed paraffin embedded (FFPE) tissue. Additionally,
evidence from our recent study on EMT states suggests that canonical cell surface markers
(CD44, CD104, EpCAM) are not sufficient to separate distinct intermediate states from one
another178. Indeed, Pastushenko et al.46 relied upon co-staining of four markers and precise
gating strategies to adequately separate these states. Thus, flow cytometry presents an
excellent approach for basic biological analysis of E-M plasticity, but has few applications for
direct use on archival patient tissues.
1.4.3b Immunohistochemistry and fluorescence
Immunohistochemistry is the most common form of immunostaining and has been used for
decades to detect and label antigens in tissue sections189. Hematoxylin and eosin (H&E) stains
for DNA and proteins, respectively, is the principal method for histological assessment of tumor
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grade and histological subtype. In addition to assessing tumor grade and histologic subtype,
IHC staining for other biomarkers is routinely performed by pathologists for certain tumors, such
as hormone receptors, HER2, and Ki67 in breast cancer, to provide prognostic and predicative
information, and to stratify tumors into molecular intrinsic subtypes190,191 (Figure 3).
Immunofluorescence (IF) staining for EMT markers, particularly E-cadherin and Vimentin
has frequently been used alongside other methods for visualizing co-expression of epithelial
and mesenchymal markers as well as discerning the sub-cellular localization of proteins.
However, it is rarely used as a comprehensive method for defining EMT states owing, in part, to
the limitation of fluorescence wavelengths that only allow visualization of a limited number of
markers simultaneously. Efforts to combine changes in cell morphology with Ecadherin/Vimentin IF staining in a predictive EMT model have been partially successful in cell
lines192, however the application of this predictive model in vivo remains unclear. An
immunofluorescence microscopy assay for cytoskeletal remodeling elements193 been
successfully implemented as a readout for EMT disruption to screen a panel of transcription
factor-targeting siRNAs to determine transcriptional nodes that control EMT75, which can be
useful for easy drug treatment and screening for future testable therapeutics targeting EMT.
Combined immunofluorescence with other techniques such as cell morphology or single cell
segmentation has distinct advantages over bulk flow or sequencing by maintaining tumor
architecture and spatial organization in the tissue. However, the limiting number of probes in
classical IF presents the same drawbacks as flow cytometry and may be insufficient to describe
the complexity of E-M states.
1.4.3c Transcription-based Methods
RNA-based, and later chromatin-based, methods of assessing EMT state have two main goals:
to generate an EMT gene signature, or to characterize EMT gene networks across a spectrum
of samples. This can be done in a variety of ways, although the goal is generally to further basic
knowledge rather than apply directly to patients (Figure 3).
Bulk RNA-seq has been repeatedly used to generate EMT gene signatures or “EMT
scores” to help standardize and define entrance into an EMT175 or partial EMT states in many
cancers176 and correlate that gene signature with poor patient prognosis. This is useful in
understanding the connection between EMT gene signatures and patient prognosis as well as
defining EMT states for new model systems178. However, many groups have put forth their own
signature or method for ranking EMT160,175,176, calling into question a standardized signature for
ubiquitous use. In a more exploratory approach, RNA-seq has been used to interrogate EMP
using either isolated clonal states within an EMT46,178, or an EMT induction and withdrawal
(MET) time course. These experiments served to delineate the specific gene networks that are
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active during the transition from epithelial to mesenchymal and back75,135 and to help distinguish
targetable transcriptional networks in aggressive or metastatic cell states. Combinations of EMT
induction and siRNA knockdown of EMT target transcription factors identified control nodes
such as TEAD2, FOSL2, SP1, and others that had not been previously associated with EMT75.
Other approaches to visualize RNA expression, such as fluorescence in situ hybridization
(FISH) probing for a panel of EMT markers, have had success in assessing EMP at a single cell
level in circulating tumor cells148 before the more widely accepted single cell sequencing
approaches were robust enough to be used in this context.
Single cell RNA sequencing has been particularly vital in assessing EMT in tumors or
cells where the bulk RNA signature may not be sufficient to describe the heterogenous
populations within each sample. This can be applied to CTCs174, tumor cells194, or as part of
induced time course135,195 to delineate EMP in these samples as well as interrogate EMP and
heterogeneity at multiple points during metastasis including the primary tumor, CTCs, and
metastatic sites to see how EMT states may work individually or cooperatively to promote
metastasis.
A leap in the field came from non-specific sequencing of accessible chromatin (ATACseq) which revealed large scale chromatin modification in response progression through an
EMT46,196,197, indicating that large transcriptional shifts may be controlled through a combination
of epigenetic and transcriptional regulation. Recently, multiple efforts have taken a multi-omics
approach, combining RNA-seq and ATAC-seq to determine these combined epigenetic and
transcriptional regulatory proteins such as CTCF, the AP-1 complex, and the RUNX
transcription factor family178,198,199.
While transcription-based approaches have provided a wealth of data and greatly
contribute to the understanding of EMT, MET, and the metastatic cascade, the cost of
sequencing, the processing times, and the inability to segregate tumor from stroma still make it
inapplicable to assess patient samples for routine diagnosis. However, these comprehensive
analyses have pinpointed specific EMT indicators for further and more directed approaches
such as multiplexed staining.
1.4.3d Multiplexed Image Based Methods
Akin to immunohistochemistry, image-based methods of assessing tumors have distinct
advantages for patient diagnosis. They are relatively easy, can be done with high throughput,
and most importantly, retain spatial organization and heterogeneity of the original tumors
(Figure 3). However, immunohistochemistry or even immunofluorescence struggles to describe
the complexity of patient tumor states that may affect disease progression and metastasis,
particularly epithelial to mesenchymal plasticity. Previous efforts have combined immunohisto-
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fluoresence for E-cadherin and Vimentin with High Content Screening (HCS), introducing a
method that combines cell segmentation, morphological evaluation, and marker expression to
determine nuanced EMT states within a tumor sample at a single cell level192. This has been
implemented with various other probes and image analysis software to combine
immunofluorescence and morphological features into a reliable patient diagnostic tool200,201.
However, this method is limited by the number of markers that can be used. Others, in efforts to
combat this issue, have relied on mass cytometry time courses to map changes and coexpression of E-cadherin, Vimentin, CD44, CD24, and others in individual cells undergoing a
TGF-b induced EMT in lung cancer177. Similar methods have been used for multiplexed
identification and stratification of heterogeneity in breast cancer patient samples with 35
different markers202. Even newer technologies such as Nanostring DSP present exciting new
platforms for high-plex spatial imaging of RNA and/or proteins. This platform is becoming
increasingly useful to deconvolute tumor heterogeneity and tumor microenvironment (TME) of
specific tumor types203. These approaches rely on precise image analysis software that has only
recently become sensitive enough to reliably segment individual cells and deconvolute
multiplexed staining approaches. Considering these technological advances, image-based
approaches to quantify EMT progression in tumors are becoming more popular and easily
implementable; these technologies have been reviewed extensively elsewhere204. Recently, we
have employed a multiplexed, multi-round tyramide signal amplification (TSA) staining method
using six canonical EMT markers was used with cell segmentation and morphological features
to define an EMT heterogeneity score and overall tumor EMT score in a model system of EMT,
and further validated in a cohort of breast cancer patient samples178. Notably, this method was
the first to reliably segmented out stromal tissue such as fibroblasts which can surround tumors
and frequently express Vimentin and ZEB1, mesenchymal markers that would skew an analysis
of tumor composition. When implemented with widely practiced immunohistochemical
approaches to determining tumor grade and composition, this method can help to elucidate the
complexity of patient tumor heterogeneity and EMT state in the clinic to better inform prognosis
and treatment regimes.
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Figure 3. Methods of assessing EMT detailing the pros and cons of each approach
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Chapter 2. Quantifying epithelial-mesenchymal heterogeneity and EMT scoring in patient
tumor samples via Tyramide Signal Amplification (TSA)
In Press, Brown et. al. Methods Cell Biology, 2022205
2.1. Abstract
Tumor heterogeneity presents an ongoing challenge to disease progression and treatment in
many solid tumor types. Understanding the roots of intra-tumoral heterogeneity and how it may
relate to the high incidence of metastasis is critical in overcoming disease relapse and
chemoresistance. The Epithelial-to-Mesenchymal Transition is a dynamic cellular program that
is co-opted by cancer cells to enhance, among others, migratory and invasive cell traits. It is a
key contributor to heterogeneity, chemo-resistance, and metastasis in many carcinoma-types,
with the intermediate or hybrid EMT state playing a critical role due to its increased tumorinitiating potential. A critical component in utilizing this knowledge in patient treatment is to first
detect and score the impact of EMT in a patient sample. Here, we provide a detailed protocol to
detect EMT states and quantify the resulting epithelial-mesenchymal heterogeneity within
tumors using a novel multiplexed immunostaining approach and analysis method. This protocol
and concept can easily be adapted using custom panels of markers to explore other sources of
tumoral heterogeneity in addition to EMT.
2.2. Introduction
Tumor heterogeneity presents an ongoing challenge to disease progression and
treatment in many solid tumor types206,207. A key contributor to both heterogeneity36–38 in solid
tumors and later stage chemo-resistance and metastasis32,33 is the epithelial-to-mesenchymal
transition (EMT). This developmental program is frequently exploited in the context of cancer to
increase migratory abilities, invasiveness, metastatic potential, and resistance to
chemotherapy34. Indeed, EMT has been demonstrated and linked to poor prognosis and
decreased survival in many solid cancer types2–4. Cells have been found to reside in multiple
stable intermediate states along the EMT spectrum45,46,52,53, which confer increased aggressive,
metastatic, and chemoresistance attributes to a heterogeneous tumor through increased stemlike characteristics49,50. Identifying and targeting EMT heterogeneity in patient tumors represents
a major hurdle in overcoming metastatic disease and therapy resistance. Despite major
advances in our understanding, the contributions of EMT research to improvements in
diagnostic pathology or cancer therapy have been minimal. One reason for this gap stems from
our inability to accurately detect and quantify epithelial-mesenchymal heterogeneity in primary
tumor specimens. Secondly, the significance of recently identified intermediate or partial EMT
states17–19 to predicting tumor prognosis and therapy response are unclear.
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In developing a method for quantifying tumor heterogeneity and EMT, we considered
multiple attributes. Firstly, we aimed to establish a method that would allow for precise and nonoverlapping staining of multiple markers on one formalin-fixed paraffin embedded (FFPE) tumor
tissue section. Secondly, we intended to develop a panel of markers that would best delineate
the spectrum of EMT states present within a tumor, and thirdly, we devised a method of
analyzing and quantifying both EMT heterogeneity (i.e., diversity of cell types) and EMT score
(i.e., overall tumor composition) of any tumor stained with this method. In order to validate these
staining and analysis methods in an appropriate model system, we used single cell clones
derived from the SUM149PT ER-/PR- inflammatory breast cancer cell line208,209. We isolated six
single-cell clonal populations, ranging from epithelial-like to mesenchymal, including three
distinct intermediate states178. These clones were ranked along the EMT spectrum relative to
one another based on expression of canonical epithelial and mesenchymal markers such as
Vim (Vimentin), CDH1 (E-cadherin), ZEB1, and SNAI1 (Snail). The “EMT clone” cell lines were
orthotopically injected into immune deficient mice to create a panel of diverse tumors ranging in
EMT states for this model. Tumor initiation, growth, and metastasis to the lung were carefully
monitored to determine differences between the clonal states for further analysis178.
To precisely stain for multiple overlapping markers in one tissue sample, we chose the
Tyramide Signal Amplification (TSA) System developed by PerkinElmer210. TSA uses enzymemediated catalysis of Horseradish peroxidase (HRP) to deposit a labeled tyramide at the site of
primary antibody detection, which remains in place after primary and secondary antibodies are
stripped away. This allows for multiplexing of six or more markers per sample while retaining
high signal output and specificity and makes assessing EMT heterogeneity in tumors rapid and
effective. This staining approach, paired with the inForm® analysis software, enables spectral
unmixing, tissue and cell segmentation, and cell phenotyping for robust analysis at a single cell
level while retaining spatial information. To delineate the EMT spectrum, we designed a panel of
six EMT markers, containing three intermediate filament proteins (KRT8, KRT14 and VIM), two
EMT transcription factors (ZEB1 and Snail), and an adherens junction protein that serves as a
hallmark epithelial marker (E-cadherin). These six markers were chosen to span the spectrum
of cell states from epithelial to mesenchymal, and have been previously shown to be coexpressed in various instances across the EMT spectrum38,48,211. Antibodies were chosen based
on immunohistochemical (IHC) staining to determine optimal antibody concentrations and
specificity without background signal.
In developing an analysis method for scoring tumors, there were two goals in mind: to
determine a metric to measure the diversity of EMT cell populations in a tumor at a single cell
level (i.e. intra-tumoral heterogeneity), and to calculate the overall cumulative EMT state of a
tumor (i.e. EMT score). Moreover, we were curious to observe if these two measures were
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dependent upon one another, or rather, two independent measures that could provide
information to understand E-M heterogeneity within a tumor. To assess tumor heterogeneity,
tumor images were scored based on a rubric of low (one major cell trait with up to one minor
trait), mid (two major cell traits with up to three minor traits), and high (three or more major cell
traits present with two or more minor traits). These scores were then used as ground truth labels
in an entropy-based feature extraction method212,213 of the mean expression per cell of all six
markers. Five-fold cross validation of a test set of 350 images verified this entropy-based
method with an accuracy of 78%178. In a parallel method to assess phenotypic composition, the
inForm® analysis software (Akoya Biosciences) was trained on a subset of tumor images to
recognize seven distinct cell phenotypes encompassing the majority cell states present in all
tumor images. These phenotypes, spanning from most epithelial to most mesenchymal are: Ecadherin only, KRT8 & E-cadherin, KRT8 and/or KRT14, Triple positive (KRT8+Ecadherin+Vimentin), KRT8/14 and Vimentin, Snail only, Vimentin only, and Vimentin & ZEB1.
These phenotypes encompass the variation of cell states that were reproducibly detectable in
the SUM149PT model as well as a cohort of breast cancer patient samples. The EMT score
was derived from a linearly weighted average of cell ratios expressing each phenotype from
epithelial to mesenchymal, spanning from 0 to 1. Finally, these two scoring metrics were used in
a multivariate Cox proportional hazard model to predict risk on overall survival to the a patient
based on the heterogeneity and EMT score of tumor at presentation (Figure4). While
heterogeneity score itself was predictive of patient survival (HR:3.9, 95% CI: 2.00-7.61,
p=6.04E-5), the significance of this finding was strengthened in a multivariate model with both
Heterogeneity and EMT score, due to the correlated nature of these methods (p=4.4E-5).
Overall, those patients with high heterogeneity (HR: 5.2, 95% CI: 2.6-10.6, P=5.2E-6) and/or
intermediate EMT scores (0.3-0.7) (HR:1.7, 95% CI:1.0-3.0, p=0.05) had a significantly poorer
survival outcome178. Code for these scoring metrics can be found on Github
https://github.com/BMIRDS/cell-heterogeneity-emtscore.
In comparison to other scoring methodologies for EMT or intra-tumoral heterogeneity,
such as single cell sequencing or proteomic analysis, this method can be performed on
formalin-fixed paraffin embedded (FFPE) tissue samples with minimal pre-processing and
requires only a small portion of tumor, such as those taken from a core biopsy or partial sample.
Here, we detail the methods used to stain, score, and analyze tumors derived from the
SUM149PT model. This method has been successfully validated in a large cohort of breast
cancer patient tumors (n=124) to predict patient overall survival178, as described above.
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Figure 4. Multiplex Staining Flowchart: Flowchart outlining the steps taken from the initial
staining process to the final quantification of heterogeneity.
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2.3 Materials
Disposables
•

Microscope cover glass (Fisherbrand 24.60mm #12-545-M)

Reagents
•

Opal 7-Color Manual IHC Kit (Akoya Biosciences # NEL811001KT)

•

Xylene (Sigma-Aldrich #XX0055)

•

100% Ethanol

•

10% neutral buffered formalin (Leica #3800598)

•

Bond Epitope Retrieval Solution (Leica #AR9961)

•

TBST Wash Buffer - 25 mM TRIS-HCl, pH 7.5; 150 mM NaCl 0.05%; Tween®20 (v/v)

•

Leica primary antibody diluent (Leica #AR9352)

•

Bovine Serum Albumen (VWR #0332)

•

Goat IgG (Life Technologies #500622)

•

Hydrogen peroxide (Sigma-Aldrich #HX0635-3)

•

ImmEdge PAP pen (Vector Laboratories #H-400)

•

HRP conjugated secondary antibodies (anti-rabbit, anti-mouse)

Equipment
•

Glass slide staining dish (Fisherbrand # 08-817 or #08-810)

•

Pressure Cooker (Cuisinart)

•

Vectra3 or Vectra Polaris Slide scanning microscope

•

Microwave

2.4 Methods
OPAL Optimization (For developing new marker panels):
Adapted from the OPAL Assay Development Guide214
Overview: Tyramide Signal Amplification (TSA) is a multiround, multiplexed method of staining
FFPE tissue with high specificity for multiple overlapping markers. It uses enzyme-mediated
catalysis of HRP-conjugated secondary antibodies to deposit a labeled tyramide or OPAL
fluorophore at the site of primary antibody detection, which remains in place after primary and
secondary antibodies are stripped away by a microwaving step. The order and concentration of
primary and secondary antibodies, as well as pairing with each OPAL fluorophore must be
carefully considered based on overall intensity of protein expression and detectability of
epitopes. Single round optimization is recommended and details can be found in the OPAL
Assay Development Guide214 from Akoya Biosciences and are summarized below.
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1. Using antibody recommended dilutions as a starting point, titrate antibody
concentrations on the tissue or tumor of choice via immunohistochemical (IHC)
approaches to determine the optimal concentration with minimal background.
2. Determine antibody-OPAL pairs avoiding spectral overlap with colocalizing proteins. As
a general rule, apply more strongly fluorescent OPALs to lower expressed proteins.
3. Build spectral library of single stained slides of each antibody and OPAL for use in
inForm® Spectral Unmixing as per instructions in the Akoya Guide214
4. Each antibody-OPAL pair should be optimized for the number of microwave cycles (i.e.
staining order) and antigen retrieval buffer pH (6.0 is sufficient for most epitopes,
although pH 9.0 can be used for some targets such as nuclear proteins)
Staining:
Note: Throughout the staining process, it is critical to not let the tissue dry out, either during
washes or the microwave steps or staining will be uneven. Vertical glass staining dishes can
minimize evaporation (Table 2)
1. Obtain sections of formalin fixed paraffin embedded (FFPE) primary tissue of choice.
This can also be done on Tumor Microarrays (TMAs) to maximize staining. Include an
unstained slide for background fluorescence during unmixing
2. Bake slides for 2 hours at 60ºC dry oven to melt the paraffin wax, followed by 3x tenminute washes with Xylene
3. Rehydrate the tissue with descending gradients of ethanol (100% x2, 90% x2, 70%,
50%, 30%, water) for ten minutes each
4. Fix the tissue with 10% neutral formalin for 30 minutes, followed by three washes with
Tris-Buffered Saline with Tween® 20 (TBST, ~100mL depending on container)
5. Submerge the slides in an antigen retrieval citrate buffer (pH 6.0, ~100mL depending on
container) and place in a pressure cooker on high for 20 minutes. Alternate antigen
retrieval methods can be used such as microwaving on high for 15 minutes. Allow
cassettes to cool before washing with TBST.
6. To deactivate endogenous peroxide activity, block with 3% Hydrogen Peroxide (H2O2)
diluted in ddH2O for 10-15 minutes. Wash once with water and once with TBST
7. Carefully dry the slides (minimally) and circle the tissue area with a high-quality PAP pen
to create a hydrophobic barrier for on-slide staining
Note: After the addition of OPAL fluorophores, keep slides in the dark at all steps
8. Block the tissue (including background slide) in 1% bovine serum albumen (BSA) diluted
in an antibody diluent of choice (~200-300uL, to cover tissue) for 10-30 minutes at room
temperature. Goat IgG containing diluents or additives can decrease background and
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are suggested (e.g., 9mL antibody diluent, 1mg BSA, 1mL Goat IgG). No washes are
required after blocking.
9. Incubate tissue on-slide with Primary Antibody (see table) diluted in an antibody diluent
of choice for 30 minutes at room temperature. Wash 3x three minutes with TBST.
Incubate background slide in plain diluent.
10. Incubate tissue with an HRP-conjugated secondary antibody against the primary
antibody from step 3 for 30 minutes at room temperature. Wash 3x three minutes with
TBST.
11. Dilute TSA OPAL fluorophore in 1X Plus amplification diluent (provided with OPAL
reagent kit) or antibody diluent of choice. Incubate tissue for 10 minutes, being sure to
keep incubation times consistent between tissue as fluorophores are very sensitive.
Wash 3x three minutes with TBST.
12. Conjugate OPAL to the antibody epitope and remove primary and secondary antibodies
through microwaving. Submerge slides (including background slides) in antigen retrieval
citrate buffer (pH 6.0) and microwave at full power until buffer begins to boil (100ºC),
followed by 15 minutes at 20% power. Ensure that enough buffer is used so that tissue
remains submerged throughout the microwave process. Allow slides to cool, away from
light, for ~20 minutes. Wash once with ddH2O and twice with TBST.
13. Repeat steps 1-5 for all antibody-OPAL pairs. Slides can be stored overnight in 4ºC after
blocking (store in TBST) or after microwaving (store in citrate buffer).
14. Dilute Spectral DAPI (provided with OPAL kit) or another fluorescent DAPI in TBST and
incubate tissue (not including background slides) for 5 minutes at room temperature.
Wash with phosphate-buffered saline (PBS) 3x three minutes followed by a wash with
ddH2O.
15. Carefully dry tissue and slides with minimal light exposure and mount to coverslip with
ProlongDiamond or another mount media without DAPI stain. Allow to dry completely
before imaging (~24-48hrs).
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Table 2. Primary and secondary antibodies and OPALs in order for TSA staining

#
1

Primary Antibody
Snai1 1:400
CST #3895

2

KRT8 1:300
Invitrogen PA5-29607

3

KRT14 1:1000
Invitrogen MA5-11599

4

Vimentin 1:300
CST #5741

5

E-cadherin 1:500
BD #610182

6

ZEB1 1:1000
Invitrogen PA5-82982

Secondary Antibody
Goat anti-mouse HRP
1:1500
Goat anti-rabbit HRP
1:1500
Goat anti-mouse HRP
1:1500
Goat anti-rabbit HRP
1:1500
Goat anti-mouse HRP
1:1500
Goat anti-rabbit HRP
1:1500
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Opal (TSA)
Opal 620 1:500
Opal 540 1:1,000
Opal 520 1:150
Opal 690 1:150
Opal 650 1:500
Opal 570 1:600

Imaging and Analysis
1. Scan in the tissue slides on a Vectra®3 or Vectra Polaris® (Akoya Biosciences) slide
scanner at 20x magnification, setting exposure times based on samples with average to
high intensity for each marker.
2. For whole tissue slides, it is recommended to avoid areas of necrosis or those lacking
tumor tissue when choosing Regions of Interest (ROIs) for image acquisition. The
number of images (or TMA cores) per sample should be determined by the needs of the
study.
3. Collect multiple images at 20x magnification from the Background Autofluorescence
slide, being sure to include any autofluorescent tissue or cells such as red blood cells.
4. Determine a subset of images that reflect both marker distribution as well as tissue
architecture for use in algorithm training on InForm.
5. For details on inForm® Software, consult Akoya Biosciences. Briefly, images were
unmixed with spectral libraries made in the same tissue type (Figure 5A), within 4
months of imaging. Tissue was segmented with the Adaptive Tissue Segmentation step,
for tumor and stromal tissue using the Large pattern finder and trimming 6 pixels in to
tumor tissue (Figure 5B). Cell segmentation was trained using Adaptive Cell
Segmentation on DAPI (nuclear), K8 (cytoplasm), Vimentin (cytoplasm), and E-cadherin
(membrane) (Figure 5C). Finally, phenotypes were determined by eye to encompass the
majority of cell phenotypes identifiable within the training set of images (Figure 5D).
Quantification:
1. Using R studio, normalize mean marker expression for Entire Cell across all samples (as
a percentile of marker counts). Marker distribution violin plots can be used to validate
correct phenotyping (i.e., K8 & E-cadherin phenotype expresses high K8 and E-cadherin
only) (Figure 5E).
2. Tumor heterogeneity and EMT scores can be calculated using the source code available
on GitHub (https://github.com/BMIRDS/cell-heterogeneity-emtscore, Figure 5F & G)178.
Briefly, heterogeneity is generated using penalized logistic regression based on
entropies of mean marker cell expressions to identify markers and cellular compartments
(Nucleus, Cytoplasm, and Membrane) that contributed most to the variability in the
ranked tumor images. 134 entropy-based features extracted, and 13 of them were
selected by Recursive Feature Elimination (RFECV)215 as most relevant. Logistic
regression classified sample heterogeneity into three levels: low, mid, and high. Target
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labels were determined from the rubric: low (one major cell trait with up to one minor
trait), mid (two major cell traits with up to three minor traits), and high (three or more
major cell traits present with two or more minor traits). These were used to train and
validate the algorithm using 70% training (n=286) and 30% test images (n=123) in a fivefold cross validation (Figure 5F). To generate the EMT score, the seven derived
phenotypes were weighted from epithelial to mesenchymal (E-cadherin only -3, KRT8 &
E-cadherin -2, KRT14 only -1, Triple positive +1, Snail only +2, Vimentin only +3, and
Vimentin & ZEB1 +4) and applied to a multivariate logistic regression (Figure 5G).
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Figure 5: Analysis and Quantification of EMT states by inForm analysis. A) Composite
image B) tissue segmentation C) cell segmentation and D) cell phenotyping stages of
inForm analysis. E) Violin plot of the percentile normalized expression of each marker by
phenotype, used to validate accurate phenotyping. F) An example of Heterogeneity and G)
EMT scores from the SUM149PT model.

- 35 -

2.5 Concluding Remarks
Here we have presented a method for analyzing the EMT composition and tumor heterogeneity
of patient tumors. This method was developed in an orthotopic mouse model of basal-like breast
cancer and validated in a cohort of breast cancer patient samples to predict patient outcomes
based on tumor composition and heterogeneity. This multiplexed staining and image analysis
pipeline represents a novel method for quantifying EMT in a variety of patient samples to help
supplement traditional diagnostic pathology and inform treatment regimens.
Limitations
Limitations to this method include access to software and applicability in other cancer types.
inForm analysis software is expensive and is best acquired though an institutional core facility
as a shared resourse. Antibodies used in this method are, as of now, readily available and
target both mouse and human version of each protein. These six markers have been developed
to stratify EMT states in human triple negative breast cancer, although they have been validated
in other breast cancer subtypes. However, this panel may require further validation and
tweaking for other solid tumor types. Intra-tumoral heterogeneity can vary drastically within the
tumor and therefore, whenever possible, more than one region or core should be used per
sample to accommodate for this.
Notes:
Throughout the staining process, it is critical to not let the tissue dry out, either during washes or
the microwave steps or staining will be uneven. Vertical glass staining dishes can minimize
evaporation.
After the addition of OPAL fluorophores, keep slides in the dark at all steps.
Regarding image analysis:
To ensure correct image unmixing and analysis, carefully choose a training set of images that
best represents the diversity of images within the test set. This includes high and low stromal
infiltration, as well as areas of high and low expression for each marker. Correct tissue
segentation, cell segmentation, and cell phenotyping is best achieved through multiple rounds of
algorithm training and retraining at each step to ensure that these steps are as accurate as
possible. Cell segmentation includes “cytoplasm pixel size” and “membrane pixel size” – these
should be adjusted to accommodate the average cell size and shape present in the tissue.
For cellular phenotyping in particular, we recommend choosing cells for the training set where
the phenotype is 90-100% certain, and correcting and retraining by eye as needed. Additionally,
we recommend visualizing the counts per cell compartment (hover arrow) in inForm to correctly
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assign phenotypes. The more cells identified within the training set, the more accurate this
phenotyping will be; we recommend anywhere between 5-20 “training” cells per phenotype.
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Chapter 3. Investigating the networks and effects of the intermediate EMT state on tumor
heterogeneity and patient prognosis
In Press, Brown et. al. Science Advances, 2022178
3.1 Abstract
The Epithelial-to-Mesenchymal Transition (EMT) is frequently co-opted by cancer cells
to enhance migratory and invasive cell traits. It is a key contributor to heterogeneity, chemoresistance, and metastasis in many carcinoma-types, where the intermediate EMT state plays a
critical tumor-initiating role. We isolate multiple distinct single-cell clones from the SUM149PT
human breast cell line spanning the EMT spectrum possessing diverse migratory, tumorinitiating, and metastatic qualities, including three unique intermediates. Using a multi-omics
approach, we identify CBFb as a key regulator of metastatic ability in the intermediate state. To
quantify epithelial-mesenchymal heterogeneity within tumors, we develop a novel multiplexed
immunostaining approach using SUM149-derived orthotopic tumors and find EMT state and
epithelial-mesenchymal heterogeneity are predictive of overall survival in a cohort of stage III
breast cancer. Our model reveals novel insights into the complex EMT spectrum, their
regulatory networks, and reveals how epithelial-mesenchymal plasticity contributes to tumor
heterogeneity in breast cancer.
3.2 Introduction
The Epithelial-to-Mesenchymal Transition (EMT) is a developmental cellular program
frequently coopted by cancer cells34 and is a key contributor to intra-tumoral heterogeneity36–38,
chemo-resistance and metastasis32,33. Rather than being a switch from an epithelial to a
mesenchymal state, increasing evidence points to the existence of intermediate EMT states,
wherein cells co-express both epithelial and mesenchymal traits45–51. These robust stable and
metastable transition states possess unique characteristics45,46,52,53 and contribute to the
complex heterogeneity of tumors and their overall metastatic behavior8,56. While much work has
been carried out identifying and characterizing EMT-inducing transcription factors70,71,73,134, the
transcriptional and epigenetic networks responsible for the stability and maintenance of the
midpoints along the EMT spectrum are poorly defined. In addition, there are currently no
approaches to identifying and quantifying intermediate EMT subpopulations within patient
tumors to evaluate their prognostic significance. Using single-cell clonally isolated derivatives of
the SUM149PT breast cancer cell line, we systematically interrogate how each EMT state
independently contributes to heterogeneity and influences metastatic progression, uncovering
the role of CBFb in stabilizing and maintaining metastatic capability in certain intermediate
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states. We develop an entropy-based model to quantify phenotypic heterogeneity and EMT
status and primary patient tumors using SUM149PT-derived tumors stained with a panel of six
EMT markers as a training set. The cell states captured in the SUM149PT model are
represented in a cohort of patient tumors and are predictive of overall survival in these patients,
laying the foundation for quantification of epithelial-mesenchymal heterogeneity (EMH) and
understanding the role of the intermediate EMT state in tumor progression.
3.3 Results
3.3.1 Generation of a Model to study EMT
3.3.1a Single cell clones reside in multiple distinct EMT states
We derived single cell clones from the SUM149PT ER-/PR- inflammatory breast cancer
cell line208,209 stratified by expression of CD44 and CD104 (ITGb4)52 (Figure S1A). Six single-cell
derived clonal populations were isolated, ranging from epithelial-like I to mesenchymal (M1 and
M2), including three distinct intermediate states (EM1, EM2, and EM3) – hereafter referred to as
“EMT clones” (Figure 6A, Figure 7A). Briefly, the SUM149PT cell line was sorted into three
populations stratifying the EMT spectrum (Figure 7A) and single cells were sorted into 96-well
plates from which fourteen single-cell derived clonal populations were chosen and isolated
based on morphological characteristics. Of these fourteen, six were chosen to best represent
the spectrum of states within the SUM149PT parental cell line. These clones, which stably
retained their EMT states in vitro, were ranked along the EMT spectrum relative to one another
based on expression of hallmark epithelial and mesenchymal markers such as Vim (vimentin),
CDH1 (E-cadherin), ZEB1, and SNAI1 (snail) (Figure 6C & D), as well as by variable migratory
and invasive characteristics in vitro (Figure 6B). While the mesenchymal clones exhibited
greater migratory and invasive ability than the epithelial clone, the intermediate clones displayed
2-10-fold higher migratory and invasive potential than the mesenchymal clones. These data
suggest that earlier EMT studies did not discern intermediate states from mesenchymal ones
when assessing these specific characteristics. Classic flow cytometry approaches employing 23 markers were insufficient to distinguish between the intermediate states (Figure 7D). By other
measures, however, the intermediate clones exhibit differences in cell migration (Figure 6B),
EMT marker expression (Figure 6C & D), cell morphology (Figure 6E) and expression of
vimentin and E-cadherin (Figure 6F). Interestingly, the three intermediate clones most closely
resemble the characteristics of the parental line in migratory and invasive ability in vitro (Figure
6B) and co-expression of E-cadherin and vimentin (Figure 6F), as well as their overall
transcriptional profiles determined by unsupervised hierarchical clustering of Pearson’s
correlation coefficients following RNA-sequencing (Figure 7E). Notably, there were no
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substantial genetic differences between clones E, EM1, EM2, EM3 and M1, with M2 exhibiting
some SNP and INDEL variations (Figure 7B & C), indicating that the phenotypic and functional
differences between these intermediate clones are likely driven by non-genetic mechanisms216.
Various methods have been developed to quantify the extent to which cells undergo an
EMT and determine an absolute comparable EMT score175,176,217, which have been reviewed
recently160. When applied to our model, all three methods – MLR176, KS175 and 76GS217 – predict
that E through EM3, i.e. the epithelial and three intermediate clones, fall within the intermediate
state, while M1 and M2 are mesenchymal (Figure 6G, Figure 7F & G). When plotted amongst
the 59 breast cancer cell lines from the Cancer Cell Line Encyclopedia (CCLE), these clones fall
along the intermediate and more mesenchymal end of the spectrum (Figure 6H, Figure 7F&G,
Supplemental Table 1). This spread of EMT states is most relevant in the context of studying
metastasis as many highly epithelial breast cancer cell lines such as those seen in this
comparison (Figure 6H) exhibit less migratory and invasive characteristics218, which contribute
significantly to metastatic potential. Notably, the parental line scored closer to the epithelial I
clone in most methods (Figure 6G, Figure 7F & G).
Heterogeneity in breast cancer cell lines and presence of intermediate states has been
validated across many breast cancer cell lines and EMT models46,135. To further corroborate
these findings in the SUM149PT model, we validated the presence of multiple EMT states in
four canonical breast cancer cell lines, which range from intermediate to mesenchymal in their
EMT scores – HCC1143, HCC38, Cal-51 and MDA-MB-231 (MLR EMT score: 0.26, 0.76, 1.06,
and 1.93, respectively; Figure 6H). All four cell lines are comprised of heterogeneous
subpopulations along the epithelial-mesenchymal spectrum to varying degrees, as revealed by
their co-expression of E-cadherin, vimentin, and KRT8, matching those observed in the
SUM149PT parental cell line (Figure 6I, Figure 7H). Our model, thus, highlights the presence of
multiple distinct intermediate EMT states that are also found in other breast cancer cell lines,
validating the suitability of this model further investigation of each state’s role in tumor
development and metastasis.
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Figure 6: Heterogeneous cell line SUM149PT contains multiple distinct EMT states that
can be isolated as single cell clones.
A) A schematic of the Flow cytometry method used to isolate single cell clones that present as
an epithelial (E), three distinct intermediate (EM1, EM2, and EM3), and two mesenchymal (M1
and M2) EMT states. B) In vitro assessment of clonal migratory and invasive characteristics
as measured in a standard transwell assay (n=3, SD, p-value ****<0.0001, ***<0.001, *<0.05).
Canonical EMT marker expression levels as determined by (C) Quantitative RT-PCR (SD,
n=4) or (D) immunoblotting to rank SUM149 clones along the EMT spectrum. E) Bright field
and F) immunofluorescent images of EMT clones in vitro stained with Vimentin and E-cadherin
displaying cell morphology and marker expression & localization, respectively. G) EMT
signature of EMT clones and parental line generated from the ordinal Multinomial Logistic
Regression method of gene scoring and H) distribution of EMT score of the EMT clones among
other breast cancer cell lines from the Cancer Cell Line Encyclopedia (CCLE). I)
Immunofluorescent staining for E-cadherin (red), Vimentin (green), and KRT8 (white) of four
triple negative breast cancer lines (two intermediate – HCC38 and Cal-51, one epithelial –
HCC1143, and one mesenchymal – MDA-MB-231) from the CCLE displaying heterogeneous
phenotypes.
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Figure 7: Heterogeneous cell line SUM149PT contains multiple distinct EMT states that
can be isolated as single cell clones
A) Fluorescence Assisted Cell Sorting (FACS) cytometry gating strategy to segregate
individual EMT states from the heterogeneous breast cancer cell line SUM149PT, including
epithelial (CD104hiCD44lo), intermediate (CD104hiCD44hi), and mesenchymal
(CD104loCD44hi) to generate clonal cell lines. B) Enrichment of clone specific variants (InDels
and C) SNPs) among variants found in E. Fisher’s Exact Test n comparison to clone E D)
FACS plots of EMT clones stained with CD44 and CD104. E) Unsupervised hierarchical
clustering of Pearson correlation coefficients of clone-specific gene expression profiles
derived from RNA-sequencing (n=3207 genes) in comparison to clone E. F) EMT signature
of EMT clones and parental line generated from the KS and G) 76GS methods of gene
scoring plotted among other breast cancer cell lines from the Cancer Cell Line Encyclopedia
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epithelial – HCC1143, and one mesenchymal – MDA-MB-231) from the CCLE displaying
heterogeneous phenotypes.
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3.3.2 Characterizing in vivo roles of multiple EMT states
3.3.2a Intermediate clones possess high tumor-initiating cell frequencies
In vivo tumor initiation and growth further highlighted the individuality of these EMT
clones. Upon orthotopic injection, the parental cell line was able to initiate and form tumors more
rapidly than the other clones (Figure 8A). Tumor growth analysis with a bimodal linear mixed
model219 revealed that the three intermediate clones were able to initiate tumors at the same
rate as the parental line (Initial phase Holm adj. p-val <0.05) (Figure 8A & C), but exhibited a lag
in growth (Exponential phase Holm adj. p-val <0.003). The epithelial I and two mesenchymal
(M1 & M2) clones both failed to initiate tumors as readily or, in the case of the mesenchymal
clones, grow as rapidly as the parental and intermediate clones (Holm adj. p-value < 0.01).
Increased tumor growth corresponded with decreased survival, with the parental line exhibiting
shortest survival post-injection, and the mesenchymal clones the longest (Figure 8B). Limiting
dilution analyses revealed a high tumor-initiating cell frequency in the parental and intermediate
clones, with all mice forming tumors by eight weeks (Figure 8C). The two mesenchymal (M1&
M2) possessed the lowest tumor initiating cell frequencies at eight weeks (0 and 1/75,975,
respectively) despite expressing high levels of CD44 expression, a marker frequently correlated
with increased stemness and tumor initiating ability49,50,154 (Figure 7D & 9B). All clones
generated high-grade, poorly differentiated, invasive ductal carcinomas of no special type
(ductal). Clone M1 tumors notably exhibited 50% squamous differentiation, and clone M2
showed abundant spindle cell morphology (Figure 9A). Tumor growth and TIC frequencies
indicate that, while the intermediate EMT clones may represent a population with high tumorinitiating potential, a heterogeneous population such as the parental line is able to enter an
exponential growth phase more rapidly. Notably, as with the clonal cell lines, flow cytometry was
not able to distinguish between tumors of different clonal origin despite significant differences in
growth and survival (Figure 9B).
3.3.2b EMT state impacts outgrowth of metastasis
For the purposes of monitoring metastatic outgrowth in vivo, derivatives of each EMT
cell line stably expressing a Luciferase-IRES-ZsGreen construct were generated, which allowed
for both live and post-mortem detection of tumor cells. As has been observed previously for
SUM149PT220, the parental line and all clones metastasized to the lung, with varying success,
as seen by fluorescence (Figure 8D). No other metastatic lesions could be detected by
luciferase or fluorescence.
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To precisely delineate the propensity of the clones to form micro- and macro-metastasis,
lungs from animals bearing orthotopic tumors were fixed and stained with H&E and counted for
micro- (<10 adjacent cells) and macro- (>10 adjacent cells) metastases (Figure 8E & F). The
three intermediate (EM1-3) clones seeded higher numbers of micro-metastatic lesions per lung,
compared to the most epithelial I and most mesenchymal (M2) (p-value <0.05). Within this
group, clones EM1 and EM3 seeded higher numbers of macro-metastases compared to EM2
(Figure 8E), although differences between the intermediate clones were not statistically
significant. Interestingly, while exhibiting the highest rate of tumor growth and poorest survival,
the parental line seeded fewer lung metastases than the intermediate clones, suggesting that
other mechanisms could be contributing to mortality.
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Figure 8: Differences in primary tumor growth and metastatic potential between EMT
clones.
A) Tumor growth curves measured weekly following orthotopic injection of clonal and parental
cell lines at 2,500 cells exhibit exponential growth differences between EMT states
(TumGrowth219 piecewise regression model breakpoint = 6wks, ***Holm adj. p-value
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C) Tumor initiating cell frequency calculated by limiting dilution assay with cells injected at
250k, 25k, and 2.5k cells per flank. TIC calculated at 8 weeks post injection. D) Lung sections
collected at time of maximum tumor burden (2cm3), with GFP labeled tumor cells, following
orthotopic injections as in (A). E) Lungs fixed and stained from (A) with H&E and enumeration
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micro p-val < 0.02 macro p-value = n.s.). F) Representative brightfield images of micro- and
macro- metastases from one mouse lung (EM1).
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3.3.3 Identification of transcriptional networks that sustain EMT states
3.3.3a Transcriptomic profiles reveal shared intermediate gene signature
Given the lack of genetic differences between the clones, we hypothesized that the
clonal variations in EMT state were driven by alterations in their transcriptional profiles. Using
bulk RNA-sequencing (RNA-Seq) of each clone, alterations in the expression levels of various
transcription factors were analyzed using the epithelial clone E as a benchmark. Principal
Component Analysis (PCA) demonstrates clustering of the parental line, intermediate EM and E
clones (Figure 10A & B), whereas the two mesenchymal clones (M1 & M2) share no overlap
between themselves or any other cluster. This indicates that the EMT clones do not reside in a
linear spectrum, but rather embark upon multiple distinct trajectories. Unsupervised hierarchical
clustering of the 500 most variable genes across all clones reveals distinct transcriptional
programs separating the three intermediate clones from the epithelial I and mesenchymal (M1 &
M2) ones (Figure 10D). Within this intermediate cluster, EM2 and E are again distinct from the
remaining intermediates and parental line (Figure 10B & D). Differential expression analysis
revealed 581 shared genes were significantly differentially expressed (adjusted p<0.05) in all
clones when compared to E, with 1881 genes shared between the two mesenchymal clones
and 178 shared between the three intermediate clones (Figure 10C, Figure 11A, Supplemental
Table 2). Indeed, in comparison to the epithelial baseline clone E, more differentially expressed
genes are exclusive to each clone than are shared between two or more clones (Figure 10C),
further corroborating the unique EMT states represented by this model. Gene set enrichment
analysis (GSEA)221 of the differentially expressed genes confirms activation of the Hallmark
EMT gene set in all intermediate and mesenchymal clones, as well as other gene sets
corresponding to cell division and chromatin remodeling, as expected (Figure 11B).
To further explore the epigenetic landscape of these clones, we employed ATAC-seq222
to determine the differential chromatin accessibility across EMT clones in comparison to the
epithelial clone E, which exhibits the most closed chromatin profile (Figure 10E). Notably, the
chromatin landscape is similarly diverse between mesenchymal and intermediate clones (Figure
11C & D), as seen in the RNA-sequencing (Figure 10D). To identify TFs with a significant
enrichment of motifs among peaks that were uniquely accessible in each clone (relative to E),
presence of transcription factor binding motifs was scanned for using Motifmatchr223, and tested
for enrichment against the background set of all identified peaks (hypergeometric test, padj<0.05) (Figure 10F). The three intermediate and early mesenchymal clones were highly
enriched for motifs of the RUNX family transcription factors (Figure 10F). The TFAP2A/B/C TF
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family also exhibit enriched binding accessibility in these intermediate and early mesenchymal
clones, albeit less significantly than the RUNX family. All three RUNX transcription factors as
well as their co-factor CBFb have been previously implicated in various cancers224–226 as well as
in metastatic progression of lung adenocarcinoma147 and triple negative breast cancer
(TNBC)108,227. Enrichment of these RUNX TF motifs is unique to the intermediate (EM1, EM2,
and EM3) and early mesenchymal (M1) clones, those that seeded the highest number of lung
metastases (Figure 8E).
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Figure 10: Identification of stabilizing transcription factors in the intermediate EMT state
by transcriptional and chromatin analysis
A) Principal Component Analysis (PCA) of the 500 most variable genes between all EMT
clones and SUM149 Parental line and B) intermediate clones only from RNA-sequencing. C)
UpSet Plot of all differentially expressed genes (referenced to clone E) that are shared and
unique to each EMT clone. D) Unsupervised hierarchical clustering of the top 500 differentially
expressed genes in all comparisons to clone E (p-value <0.05) E) ATAC-seq peak accessibility
measured as counts per million (CPM) normalized Tn5 insertions surrounding consensus
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Unsupervised hierarchical clustering of transcription factor motif enrichment (-log10 adjusted
p-value, hypergeometric test) among accessible chromatin peaks unique to each clone,
relative to E. Presence of motifs obtained from the JASPAR database were identified using
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- 50 -

3.3.3b Combined RNA-seq and ATAC-seq identifies EMT and MET networks
To provide a more comprehensive picture of the epigenetic and regulatory landscape of
EMT, we utilized a new multiomics approach, DiffTF228, to quantify TF activity and regulatory
state by integrating RNA-seq and ATAC-seq data for each clone. Similar to Motifmatchr, TF
activity was inferred by computing the fold change in chromatin accessibility between each
clone at each binding site of a given TF, once again using clone E as a baseline reference.
Inferred TF activity was visualized against RNA-seq log2 fold-change for each transcription
factor (Figure 12A, Figure 13A), facilitating simultaneous detection of TFs with increased
expression and TF activity (upper right quadrant). Analysis of the directional changes of TF
expression from RNA-seq also indicated whether the TF in question acts as an activator (green)
or repressor (red). The two mesenchymal clones revealed much larger shifts in both foldchange expression and TF activity, indicative of larger changes in their overall transcriptional
and chromatin profiles relative to E. In the three intermediate and early mesenchymal clones,
RUNX2 and RUNX3 are both amongst the most highly expressed and exhibit the highest TF
activity of all significant transcription factors (Figure 12A, Figure 13A). A list of all significant
transcription factors, their relative TF activity, and fold-change expression are included in
Supplemental Table 3. Additionally, of the transcription factors that are more accessible in the
intermediate state, expression of RUNX2 positively and TFAP2C negatively correlated with
CCLE breast line EMT scores with high significance (Figure 13B & C).
Unsupervised clustering analysis presents a clearer picture of how these TFs act in a
transcriptional network, highlighting TFs which exhibit significant changes in their activity in at
least one clone (adj. p-value <1E-15) (Figure 12B). Cluster 1 is comprised of transcription factors
that are upregulated and function as activators in the clones that exhibit increased metastatic
potential (EM1-3 and M1) – the RUNX TF family and co-factor CBFb. Cluster 2 includes factors
that increase in activity with the progression of EMT e.g., ETS1 and related factors, NFkB,
RELB, and FLI1. Cluster 3 identifies transcription factors that are activated and remain
consistently active after entrance into the EMT e.g., members and regulators of the AP1
complex. Multiple members of the KLF family of transcription factors as well as CTCF are found
in cluster 4, which exhibit a consistent decrease in TF activity following entrance into an EMT.
Cluster 5 highlights transcription factors that may be uniquely active in M2, while remaining
inactive in the other EMT clones, including FOXJ2 and FOXD3, CEBP complex members, and
ATF4. Finally, Cluster 6 delineates the transcription factors that have an overall and graded
decrease in activity as the EMT progresses. This cluster contains multiple EMT TFs such as
Snail, Slug, and ZEB1 as well as known MET promoting TFs such as GRHL1 and 2. Although
these and other canonical EMT transcription factors, such as Twist and PRRX1 are expressed
at significantly high levels (p<0.05), non-significant or decreased TF activity indicates no change
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in chromatin accessibility compared to clone E in response to this increase in expression
(Figure 13A, Supplemental Table 3). Indeed, these TFs decrease in activity while their overall
expression remains high (Figure 13A) likely resulting from strong repression of chromatin
accessibility at their epithelial target genes, potentially through HDAC recruitment85,91 or other
mechanisms at ZEB1 target promoters CDH1, EPCAM, GRHL2 (Figure 12C).
3.3.3c CBFb knockdown destabilizes EMT states
RUNX2 and its co-activator CBFb have been implicated in mammary development229,
mammary stemness107, and increased metastatic capacity in breast cancer108,230. To further
examine the roles that these transcription factors play in EMT and the propagation of a
metastatic state, we tested the effects of CRISPR-Cas9 mediated knockout of RUNX2 and
CBFb, which are uniquely expressed and active in the intermediate and early mesenchymal
clones, as well as a non-targeting LacZ control (Figure 10F, Figure 12A & B). Knockout of
RUNX2 in the intermediate clones did not result in any significant alterations to the levels of
canonical EMT markers, except a minor reduction in vimentin expression in EM2 (Figure 12D).
On the other hand, knockout of CBFb led to a downregulation of Snail and vimentin expression
in EM2 and EM3, as well as a more subtle reduction in fibronectin levels, indicating a shift to a
more epithelial state. Interestingly, the expression of all three RUNX TFs was reduced upon loss
of CBFb, likely due to its role as an essential co-factor (Figure 12D).
To determine the effect of destabilizing EMT on tumor formation and metastasis, clone
EM2 and EM3 bearing CBFb knockout or LacZ nontargeting guide RNAs were injected
orthotopically into NSG mice. These cell lines express high levels of both RUNX2 and CBFb in
comparison to clone E (Figure 12B), and form predominantly either micro- or macrometastases, respectively, in the lung (Figure 8E). Interestingly, in EM2, and to a lesser extent
EM3, CBFb knockout accelerated the timepoint at which tumors were first observed (Initial
phase Holm adj. p-val < 0.001) and time to tumor burden (Figure 12E). However, these tumors
had a near complete absence of metastasis to the lung (Figure 12F). In contrast, RUNX2
knockout did not appear to have any significant effects on tumor formation or metastasis, likely
due to compensation from the other RUNX transcription factors. Thus, we conclude that loss of
CBFb destabilizes the intermediate EMT state in clones EM2 and EM3, leading them to acquire
a more epithelial state that, despite being more proliferative lacks lung-metastatic capacity.
We then leveraged data from The Cancer Genome Atlas (TCGA) to determine whether
CBFb expression could, on its own, serve as a single gene biomarker for patient prognosis.
However, like many other single markers that have not been strong predictors of outcome231,232,
CBFb expression alone is not associated with any differences in patient overall survival in the
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TCGA-BRCA cohort, adjusting for age, stage, and PAM50 molecular subtype (HR: 1.03, p-value
= 0.834) (Figure 13E). Other biomarkers such as ZEB1, Snail, and Twist have been tested as
prognostic biomarkers across multiple cohorts with varying success and predictive power233,
however, no single biomarker has proven robust enough to be adopted into the clinic to predict
metastatic disease outcome. This further indicates the need for a more nuanced multimodal
metric to describe and identify intermediate EMT states within patient samples if EMT is to be
leveraged as a diagnostic and prognostic tool.
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Figure 12: Identification of stabilizing transcription factors in the intermediate EMT state
by multi-omics analysis
A) Advanced volcano plot of highly significant transcription factors, highlighting the RUNX family
Transcription Factor activity, relative to clone E determined by diffTF from ATAC-seq along the Xaxis (label cutoffs at 0.1, -0.1 TF activity), plotted against Log2 fold gene expression values of
transcription factors on the y-axis (label cutoffs at 1, -1 log2 fold). Transcription Factor
classification, determined by transcription factor expression, displayed in bubble color, and
number of transcription factor binding sites used to determine TF activity plotted as bubble size.
B) Unsupervised hierarchical clustering of TF activity scores (Z-score transformed) compared to
clone E (adj. P-value <1E-15, asterisk indicates n.s. in that comparison). Right hand side displays
TF classification, determined by changes in TF expression (diffTF), as an activator, repressor, not
expressed, or undetermined. C) Peak accessibility of Tn5 normalized, merged coverage of three
canonical ZEB1 target genes, CDH1, EPCAM, and GRHL2 across all clones from ATACsequencing. ZEB1 TF motifs highlighted above signal tracks. D) Protein levels of canonical EMT
markers determined western blot following CRISPR-Cas9 mediated knockout of LacZ, RUNX2,
and CBFb in late intermediate and early mesenchymal clones. E) Tumor growth curves measured
weekly following orthotopic injection of CBFb knockout at 2,500 cells (TumGrowth219 piecewise
regression model breakpoint = 6wks, *** Initial phase Holm adj. p-value <0.0001 n=5). F) Lungs
fixed and stained from (E) with H&E and enumeration of micro (<10 adjacent cells) and macro
(10+ adjacent cells) metastatic regions (SD, n=5,
p-val <0.001 EM3 p-value = n.s.)
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Figure 13: Identification of intermediate-stabilizing transcription factor RUNX2 by multiomics analysis
A) Advanced volcano plot of highly significant transcription factors relative to Epithelial determined
by diffTF from ATAC-seq along the X-axis (label cutoffs at 0.1, -0.1 TF activity), plotted against
Log2 fold gene expression values of transcription factors on the y-axis (label cutoffs at 1, -1 log2
fold). Transcription Factor classification shown in bubble color, and TF activity plotted as bubble
size. B) MLR calculated EMT scores of all CCLE breast cancer cell lines plotted against 21Q2
Expression of RUNX2 showing a positive correlation (p-value = 0.0006) and C) TFAP2C showing
a negative correlation (p-value <0.0001). D) ATAC-seq peak accessibility measured as counts
per million (CPM) normalized Tn5 insertions surrounding RUNX1, RUNX2, and RUNX3 TF motifs
for each clone. E) Kaplan-Meier Overall Survival outcome of BRCA-TCGA patient samples
stratified by 50th percentile raw VST normalized counts of CBFb, adjusting for age, stage, and
PAM50 molecular subtype (HR: 1.03, p-val= 0.834)
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3.3.4 Exploration of tumor heterogeneity in EMT clone-derived tumors
To better understand the role that epithelial-mesenchymal (E-M) heterogeneity plays on
tumor progression and metastasis, we utilized a multi-round, multiplexed tyramide signal
amplification (TSA) approach210 to assess protein levels of EMT markers, segregating out
stromal cells that could obfuscate EMT scoring. To capture the full spectrum of EMT states, we
designed a panel of six EMT markers, containing three intermediate filament proteins (KRT8,
KRT14 and VIM), two EMT transcription factors (ZEB1 and Snail), and an adherens junction
protein that serves as a hallmark epithelial marker (E-cadherin). Tumors from each of the clones
were stained and divided into 50 regions of interest (ROI) and processed with the inForm®
analysis software (Akoya Biosciences) to generate composite images (Figure 14A). inForm®
image training algorithms were used to discern tumor and stromal composition, as well as
conduct cell segmentation (Figure 15A). Normalized percentile distributions of the arbitrary
fluorescent units (AFU) of each EMT marker, per cell, across all images provided an overview of
the overall composition of these tumors (Figure 15B), indicating that no one unique marker
signature defined any individual tumor. Overall, clone M2 tumors expressed less E-cadherin and
more ZEB1, while clone E tumors contain less vimentin, indicative of their initial EMT states invitro. To determine the extent of E-M heterogeneity within the stained images, a scoring metric
was developed using the SUM149PT clones as a training set. Tumor images were scored
based on a rubric of low (one major cell trait with up to one minor trait), mid (two major cell traits
with up to three minor traits), and high (three or more major cell traits present with two or more
minor traits) (Figure 14C). Scoring based on these criteria revealed that the intermediate EMT
clones form tumors that contain more regions of higher heterogeneity than the parental cell line
(Figure 14C). Thus, increasing levels of heterogeneity may not linearly correlate with tumor
growth or metastasis, but rather, there exists an optimal ratio of cell traits within the tumor that
determines its growth and metastatic potential. Indeed, the requirement for this optimal ratio
may explain the growth lag observed in the intermediate clones when compared to the parental
line (Figure 2A), which likely results from constraints in the generation of a requisite level of
heterogeneity from a homogenous cell culture.
3.3.4a Composition of EMT Phenotypes and E-M Heterogeneity varies by EMT clone
In a parallel method to assess tumor diversity and phenotypic composition, the inForm®
analysis software was trained on a subset of tumor images to recognize eight distinct cell
phenotypes encompassing the majority cell states present in all tumor images (Figure 15A).
These phenotypes, spanning from most epithelial to most mesenchymal are: E-cadherin only,
KRT8 & E-cadherin, KRT8 & KRT14 (KRT), Triple positive (KRT8+E-cadherin+vimentin),
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KRT8/14 & vimentin, Snail only, vimentin only, and vimentin & ZEB1. Phenotypes were
validated manually and by fluorescent marker distribution (Figure 15C). Similar to EMT marker
distribution, there were no phenotypes unique to any individual state, indicating that optimal
tumor progression may be determined by global ratios of cell states rather than the presence or
absence of an individual cell type. On either end of the spectrum, clone E and clone M2 derived
tumors are made up of over 75% epithelial (E-cad only, KRT8+E-cad, or KRT14 only), or
mesenchymal (Snail only, vimentin only, or vimentin+ZEB1) phenotypes, respectively. Tumors
derived from the intermediate clone and the parental line, meanwhile, all contained a roughly
equal distributions of epithelial and mesenchymal phenotypes (Figure 14C). These data further
support the notion that the ratio of EMT states (phenotypes), rather than the presence of any
particular state, is more reflective of tumor growth and metastatic potential.
In order to develop a scoring algorithm to assess E-M heterogeneity, three feature
extraction methods were tested using the segmented cell data files (Figure 15A). These three
approaches sought to determine the best method to assess heterogeneity: (1) an entropy-based
approach212,213 using mean marker expression of cells per image, (2) a nearest neighbor
analysis approach234 using cell phenotypes as determined above (Figure 12C), and (3) a hybrid
approach combining approaches 1 and 2 (Figure 15D). All three approaches were developed
and evaluated using a randomized subset of clone tumor images and their corresponding
heterogeneity scores according to the rubric outlined in Figure 14B as ground truths. Logistic
regression performance on unseen test data indicated a 78% accuracy for entropy-based
features of mean marker cell expressions. Five-fold cross-validation determined that the
entropy-based approach 1 (F1-score= 0.78, Wilcoxon ranking test p-value=0.004) proved to be
the most robust at correctly assessing tumor heterogeneity (Figure 15D). This shows that E and
M2 clones consisted largely of areas of low or mid-level heterogeneity, whereas all intermediate
clones were comprised of regions of high heterogeneity (Figure 14B).
In addition to scoring E-M heterogeneity, we sought to assign EMT scores to tumors
based on the ratios of epithelial and mesenchymal traits they exhibit. EMT scores were
generated by calculating the composition of cell phenotypes per image (50 images per clone)
using the linearly weighted average of cell ratios expressing each phenotype from epithelial to
mesenchymal. EMT scores range from 0 to 1, with zero being comprised of all epithelial
phenotypes and one comprised of all mesenchymal phenotypes. Rather than attaining an
equilibrated EMT state, clonal tumors held true to the EMT state of their starting populations,
with clone E tumors being predominantly epithelial (mean=0.25), intermediate (EM1, EM2, EM3)
and parental tumors maintaining an intermediate EMT score (mean=0.4-0.6), and the most
mesenchymal (M2) scoring >0.7 (mean=0.7) (Figure 14D). Clone M1 tumors also scored as
intermediate despite starting as a quasi-mesenchymal, further validating this clone as a late
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intermediate (Figure 14D). Interestingly, the variation In EMT scores between images in the
intermediate clones (EM1, EM2, EM3, & M1) and parental line was highest of all of the groups,
indicating higher intra-tumoral heterogeneity amongst tumor regions (Figure 14D). In exploring
the connection between heterogeneity and EMT scores, we found a correlation between the two
scores upon splitting the EMT score into terciles (Epithelial = 0-0.29, Intermediate = 0.3-0.69,
Mesenchymal = 0.7-1; chi-squared p-value = 1.1E-11). Low heterogeneity tumor regions
correlated with more mesenchymal EMT scores, as can be seen in M2 tumors, and epithelial
EMT scores correlate with mostly mid heterogeneity, seen in E tumors (Figure 14A, Figure
15E). Mid and high heterogeneity regions were characterized by intermediate EMT scores
despite encompassing a more diverse array of possible EMT states (Figure 14E, Figure 15E).
3.3.4b Knockout of CBFb in intermediate SUM149 clones reduces E-M Heterogeneity and EMT
score
Upon developing a metric to calculate epithelial-mesenchymal heterogeneity and EMT
score, we questioned whether the decrease in metastasis observed upon loss of CBFb (Figure
12E & F) resulted from alterations to overall EMT state, or from a change in E-M heterogeneity.
Indeed, when tumors generated from EM2 and EM3 CBFb knockout clones were stained with
the multiplexed immunofluorescence panel, loss of CBFb led to the formation of tumors with
overall lower, more epithelial EMT scores (EM2 Fisher’s p-val=3.5E-7, EM2 Fisher’s p-val=4.0E-5
; Figure 14F, Figure 15F). Clone EM2 additionally had decreased E-M heterogeneity (EM2
Fisher’s p-val=0.05, EM3 Fisher’s p-val=0.5; Figure 15G). This reduction arises from an
increased presence of more epithelial phenotypes such as E-cadherin only and KRT8 & Ecadherin co-expressing cells, which are associated with a more proliferative state235,236, and
concurrent decrease in mesenchymal phenotypes such as vimentin, which are more invasive
(Figure 14F & Figure 15H).
3.3.4c Lung metastases contain predominately late intermediate and mesenchymal phenotypes
To further understand the roles of tumor cell E-M heterogeneity and EMT score on the
metastatic cascade, we resected the primary tumors to allow for maximal metastatic outgrowth
beyond the primary tumor burden. Briefly, intermediate and parental cell lines were
orthotopically injected and allowed to grow to a volume of 1cm3 before surgical resection. Lungs
were harvested and metastases quantified at 2.5 months post-resection, determined by burden
of the relapsed ipsilateral tumor. Micro- and macro-metastasis trends were maintained in this
later growth model, with EM1 forming a mixture of micro and macro metastases, EM2 forming
predominantly micro-, and EM3 predominantly macro-metastases.
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We subsequently used the multiplexed immunofluorescence approach to stain these
lung metastases to determine their heterogeneity and EMT phenotypes (Figure 14G). To our
surprise, all metastases, regardless of size or clone were predominantly mesenchymal in
composition, expressing very little E-cadherin or KRT8 (Figure 14G & H). EMT and
heterogeneity scores calculated from this staining revealed overall low heterogeneity and high
EMT scores, features that were infrequently exhibited in the primary tumors (Figure 14I). These
results suggest that, in contrast to trends observed in other models125, the SUM149PT tumors
give rise to metastases that are predominantly mesenchymal in nature.
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Figure 14: Multiplexed staining of SUM149 tumors and lungs identifies phenotypes and
quantifies tumor heterogeneity and overall EMT state in clone-derived and CBFb depleted
tumors
A) EMT clone-derived tumors resected at 1.5cm3 and stained with six marker EMT panel using
multiplexed immunostaining (n =~50 images per tumor) B) Empirically determined heterogeneity
scores of EMT clone-derived tumors. Rubric: Low (one major cell trait with up to one minor trait),
Mid (two major cell traits with up to three minor trait), and High (three or more major cell traits
present with two or more minor traits). C) Boxplot of EMT phenotypes generated from inForm®
cell phenotype analysis displaying the composition of each clonally derived tumor (n=~50 images
per tumor). D) EMT score distribution in clonally derived tumors generated from weighted
multivariable logistic regression of the phenotypes in C present in each tumor. E) Correlation of
EMT (tertile; Epithelial: 0-0.29, Intermediate: 0.3-0.69, Mesenchymal: 0.7-1) and Heterogeneity
score in EMT clone-derived tumor images (n=365, chi-square p-val=1.1E-11). F) Distribution of
EMT (tertile) and Heterogeneity scores in EM2 and EM3 clone-derived tumors following CBFb
knockout, compared to LacZ control tumors. G) Outgrowth lung metastases of EM1, EM2, EM3,
and parental tumors stained with six marker EMT panel using multiplexed immunostaining to
determine H) EMT phenotypes present and I) EMT and Heterogeneity scores.
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Figure 15: Multiplexed staining of SUM149 tumors identifies phenotypes and quantifies
tumor heterogeneity and overall EMT state
A) Outline of image analysis including Composite false colored image, trainable tissue
segmentation, and trainable single cell phenotyping. B) Marker distribution across all images
(n=~50) per clonally-derived tumor C) Validation of EMT phenotype selection. Normalized EMT
marker distribution (Percent AFU Expression) for each phenotype shows enrichment for
markers described in the phenotypes (i.e., K14 phenotyped cells are enriched for high
expression of K14). D) Entropy-based logistic regression scoring for three approaches to
determining heterogeneity. (1) an entropy-based approach using mean markr expression of
cells per image, determined by 13 out of 134 entropy-based feature interactions (2) a nearest
neighbor analysis approach using cell phenotypes as determined in C), determined by 26 out
of 49 feature interactions and (3) a hybrid approach combining approach 1 and 2, determined
by 18 of 183 features combined from approach 1 and 2. E) EMT clone correlation between EMT
score and heterogeneity score. F) EMT score G) Heterogeneity score and H) cell phenotypes
in EM2 and EM3 tumors upon CBFb knockout compared to LacZ control tumors (***pvalue<0.0001, *p-value <0.05).
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3.3.4d High Heterogeneity Score and Intermediate EMT states are predictive of poor survival
outcomes in patients
To assess whether the EMT phenotypes observed in our model were representative of
those observed in human breast cancer specimens, we carried out TSA immunostaining of a
tumor microarray of the CDP Breast Cancer Stage III Prognostic Tissue Microarray collected
and indexed by the Cooperative Human Tissue Network (CHTN) (Figure 16A). Following
staining with our 6-marker EMT panel, we recovered and analyze 124 cores from of both
hormone positive (n=86) and hormone negative (n=38) patients with long term survival follow-up
spanning 250 months. All eight phenotypes were reproducibly represented across all patient
tumors (Figure 16A, Figure 17A) and ratios of epithelial and mesenchymal phenotypes follow
similar trends to the SUM149PT clonal model (Figure 17B). These data serve to validate the
SUM149PT clones as a model to study various states along the EMT spectrum.
Cores were phenotyped and analyzed as previously described to generate a
heterogeneity score and EMT score, again segregated into terciles, for each patient (Figure
16B, Figure 17C). Overall, high heterogeneity is associated with a more mesenchymal EMT
score, while low heterogeneity is associated with an epithelial EMT score (Fisher’s exact test pvalue = 4.4xE-5, Figure 16B & C, Figure 17C). While this differs from trends seen in the
SUM149PT model (Figure 14E, Figure 15E), the samples in this cohort better represent the
population distribution of stage III breast tumors. In survival models adjusting for patient age and
hormone receptor status with all samples that passed QC (n=124), patients with a high
heterogeneity score had significantly worse overall survival (HR: 5.2, 95% CI: 2.6-10.6, P=5.2E6

), as did patients with intermediate EMT scores (HR:1.7, 95% CI:1.0-3.0, p=0.05) (Figure 16D

& E). While high heterogeneity score on its own remained predictive of poor patient outcome,
EMT score alone was not associated with survival (Figure 17D, HR(high):3.9, 95% CI: 2.007.61, p=6.04E-5). As these metrics describe associated yet independent metrics of tumor
complexity and EMT status, our results further demonstrate nuances of tumor heterogeneity in
disease progression. When sub setting for hormone negative disease (n=36), which is known to
exhibit increased intra-tumoral heterogeneity36, high and low heterogeneity were both
associated with significantly worse overall survival (HR (high): 16.7, 95% CI:4.2-66.6, p=6.5E-5;
HR (low): 7.9, 95% CI:2.3-27.1, p=0.001) (Figure 16F, Figure 17E), as was an intermediate
EMT score (HR: 3.43, 95% CI: 1.04-11.3, p=0.042). While the correlation between low
heterogeneity and outcomes was surprising, it could be a result of a subset HR- patients whose
tumors score as low heterogeneity/mesenchymal EMT (Figure 17F), similar to the M2 clone in
our HR- SUM149 clonal model (Figure 15E). In the context of these patient tumors, poor
survival outcomes could be a result of a bottlenecking event following chemotherapy
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administered to patients, which typically results in the outgrowth of more homogenous resistant
clones that are more aggressive and difficult to treat26. Hormone positive disease showed
similar trends to the overall model (Figure 17G).
We then sought to explore whether the CBFb co-factor, which we identify as a key
regulator of the intermediate state, could hold predictive value for survival outcomes as a single
marker. Sequential slides matching those used for the multiplexed immunofluorescence
approach above were stained for CBFb using immunohistochemistry and scored as negative,
weak, moderate, or strong for CBFb expression and penetrance within the sample core, noting
nuclear or cytoplasmic localization (Figure 17H). An H score such as those used to define ER
expression237 was calculated using the strength of expression (0-3) multiplied by percent
positively stained cells. Presence or absence of CBFb (negative vs. any staining) was not found
to be associated with overall survival in these patient samples (HR (CBFb +): 1.42, 95%
CI:0.89-2.25, p=0.132; Figure S6I) nor was H-score, adjusting for age and hormone receptor
status (HR: 0.1, 95% CI:0.1-1.0, p=0.845). While CBFb plays an important role in metastasis
through stabilization of the intermediate EMT state, and may represent a potential molecular
target for future therapeutics, its expression alone is not predictive as a biomarker for patient
survival.
Overall, these analyses demonstrate a novel method for scoring patient samples,
displaying an increased risk of death in patients with highly heterogeneous tumors that are
comprised of intermediate EMT phenotypes. Moreover, they display the power of a multiplexed
marker panel over a single biomarker, which was unable to correlate with patient survival.
Together, this highlights the importance of tumor heterogeneity and EMT state in understanding
and predicting patient prognosis as well as the benefit of combinatorial approaches in describing
tumor heterogeneity.
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Figure 16: High tumor heterogeneity and intermediate EMT states are associated with
poor prognosis in patient tumors
A) Stage III breast cancer patient tumors (n=124) stained with six marker EMT panel using
multiplexed immunostaining B) Stage III breast cancer cohort tumor E-M Heterogeneity (EMH)
score, determined by an entropy-based model of marker distribution at a single cell level per
image, trained and validated by the SUM149 clone tumors, plotted with EMT score (tertile;
Epithelial: 0-0.29, Intermediate: 0.3-0.69, Mesenchymal: 0.7-1) generated from weighted
multivariable logistic regression of the phenotypes present in each tumor for each patient
sample C) Correlation of EMT and Heterogeneity scores from B (Fisher’s exact test p=4.4E-5).
D) Kaplan-Meier plot of overall survival stratified by heterogeneity score. Hazard ratio and pvalue reported from E) a forest plot of Multivariate Cox Proportional Hazard model of overall
survival for Heterogeneity Score and EMT score accounting for age and subtype. F) KaplanMeier plot of overall survival in hormone negative patient samples stratified by heterogeneity
score. Hazard ratios and p-values reported from multivariate Cox proportional hazard model.
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patient samples validates SUM149 model and presents a novel diagnostic tool
A) Validation of EMT phenotype selection in patient tumors. Normalized EMT marker distribution
(Percent AFU Expression) for each phenotype shows enrichment for markers described in the
phenotypes (i.e., K14 phenotyped cells are enriched for high expression of K14). B) Proportion
of eight EMT phenotypes across all patient samples (n=124) segregated by hormone status.
EMT percentile normalized marker distribution of all staining markers across 18 patient tumors
stained with EMT marker panel. D) Univariate Cox Proportional Hazard table of Heterogeneity
score and EMT score, respectively, controlling for Age and Subtype. E) Forest plot of
multivariate cox proportional hazard model in hormone negative disease. F) Distribution of
heterogeneity and EMT scores (terciles) in patient samples stratified by hormone status G)
Kaplan-Meier plot of overall survival by Heterogeneity score in hormone positive disease.
Hazard ratio from multivariate cox proportional hazard model. H) Immunohistochemical staining
and I) Kaplan-Meier plot of overall survival of CBFb staining in patient samples (n=124).
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3.4 Discussion
Our study encompasses a comprehensive analysis of the spectrum of EMT states
represented within a breast cancer cell line to interrogate the nuances of each state, their
respective contributions to tumor initiation and metastasis, and their epigenetic regulatory
networks. We uncover the presence of multiple unique EMT states within the intermediate EMT
category, as well as two distinct mesenchymal-like states, suggesting multiple, non-linear
trajectories for EMT as has been previously shown135,238. These states were verified by flow
cytometry (CD44 and CD104) and ranked by EMT scores among other CCLE breast cancer cell
lines, where they fell between an early intermediate and mesenchymal. While this model does
not span from one extreme state to the other, it represents the EMT spectrum within
SUM149PT, a cell line that is classified the BL2 molecular subtype of TNBC239, reflecting the
heterogeneous nature of this subtype. We used the relative EMT states between the clones to
study the epigenetic heterogeneity of metastatic breast cancer within an isogenic background
and interrogate the fitness of each individual state. While the three intermediate EMT clones
possess the highest migratory and invasive potential in vitro, they are outperformed in tumorinitiating ability and growth by the parental cell line, which, by RNA-seq clustering most closely
resembles the epithelial clone.
A concern when studying heterogeneous cell subpopulations is the retention of their
initial EMT state following their isolation and culture. All six of our clones retained their
morphological and phenotypic traits through multiple passages in culture, although we did
observe clone E drifting to acquire a more spindle-shaped morphology upon extended periods
of culture. Interestingly, all single cell clones retained their initial CD44/CD104 expression
profiles except for the most mesenchymal clone, M2, which gained the expression of CD104
following its culture as an isolated single cell clone. Given that the maintenance of EMT state is
regulated by a complex set of paracrine and autocrine signals240, it is plausible, albeit
speculative, that the loss of specific paracrine signals upon isolated culture could have resulted
in an altered state in the M2 clone that allowed expression of CD104. Nevertheless, to ensure
that all clones retain their original EMT states upon culture, their passage numbers were
restricted to below 20.
We further confirm that the intermediate EMT state exhibits higher levels of cellular
plasticity, manifesting in tumors that grow more quickly than solely epithelial or mesenchymal
cell states, and exhibit high levels of E-M heterogeneity (EMH). Moreover, this plasticity-induced
heterogeneity plays a key role in the metastatic propensity and tumor-initiating potential of these
clones. However, no one individual EMT state is capable of recapitulating the aggressive growth
and decrease in survival of the parental line. The intermediate clones, upon
xenotransplantation, experience a growth lag followed by an overdiversification, resulting in high

- 66 -

EMH-scored tumors compared to the parental line, indicating that their high levels of plasticity
enable them to attain higher levels of heterogeneity that propel tumor growth and metastasis. In
contrast, the extreme clones exhibit less plasticity, taking longer periods of time to generate
tumors that are less heterogeneous with weaker metastatic potential. The intermediate
population in isolation appears to be the most potent tumor initiator, however, the presence of
multiple states (i.e., heterogeneity) within the parental line imparts additional fitness that
provides robust and exponential tumor growth. This suggests that the presence of
heterogeneous subpopulations within a tumor confer a greater tumor growth advantage than the
presence of more homogeneous subpopulations that exhibit higher levels of plasticity. A
corollary assessment would be that a tumor benefits from harboring heterogeneous
subpopulations, only a small subpopulation of which are required to exhibit high levels of
plasticity. Future studies investigating the dynamics of expansion of this intra-tumoral
heterogeneity may elucidate how EMT phenotypes work cooperatively to support tumor growth
and progression to metastasis.
Through a multi-omics approach, we identify distinct transcriptional programs across the
EMT spectrum. The intermediate state was found to be maintained and stabilized by a subset of
transcription factors, including the RUNX family. Indeed, knockout of the co-activator of this
RUNX family of transcription factors, CBFb, results in decreased expression of all RUNX TFs in
the intermediate EMT clones that leads to tumors that metastasize at lower rates as a result of
reduced heterogeneity and increased presence of epithelial cells within the tumor. These
observations are in line with other studies that have outlined a role for RUNX2 in metastasis147,
but provide additional granularity to this work by identifying specific cell states that benefit from
the presence of active RUNX- CBFb. This study also underscores the importance of combining
the study of the transcriptional and chromatin state of cells as a means of uncovering their
underlying regulatory networks, which particularly enabled the delineation between similar EMT
states; the transcriptional analysis of these clones alone was not sensitive enough to identify
differences in many of the canonical EMT transcription factors, let alone other less variable TFs.
This is likely because TF gene expression is tightly regulated by multiple factors241 and
differences in TF activity would benefit from a higher resolution study at the chromatin level.
Finally, we develop an approach to quantifying E-M heterogeneity (EMH) and
“EMTness” within human tumors, the former showing promise in its ability to inform disease
prognosis. Previous work has sought to elucidate phenotypic intra-tumoral heterogeneity in a
manner of different contexts and analyses using an array of multiplexed staining methods202,242
as well as through single cell approaches22. Here, we sought to specifically delineate intratumoral heterogeneity (ITH) across the EMT spectrum, which has strong prognostic value for
predicting invasion and metastasis in our model. A significant challenge in the quantification of
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EMH has been the ability to discern carcinoma cells that exhibit mesenchymal traits from
stromal cell-types such as fibroblasts that express similar markers. Previous approaches to
quantify EMH have considered morphological features192 and analyzed gene expression profiles
from publicly available datasets that identify cells that have undergone EMT175,176. These
approaches, while being highly useful to study tumor cell EMT status, have been unable to
segregate stromal infiltrates and their contributions to aggregate EMT scoring. Our multiplexed
immunostaining approach, which employs a set of six EMT markers to assess EMH and EMT
score, incorporates a segmentation step which ensures that the quantification excludes stromal
elements. We were able to distinguish eight phenotypes within these EMT clone-derived tumors
with high reproducibility, which were all present in a cohort of patient tumors, validating our
approach to quantifying EMT in patient samples. Importantly, we found that patients with high
heterogeneity and overall intermediate EMT state had significantly worse overall survival than
any other group, independent of patient age and clinical subtype. Notably, CBFb expression
alone was not a successful predictor of overall survival in this patient sample cohort,
emphasizing the need for a more nuanced metric, such as the one presented here, that utilizes
a combination of markers to assess tumor diversity and complexity. Moreover, the inability of a
key regulator of tumorigenic and metastatic potential such as CBFb to predict survival is in line
with studies that identify many such proteins that play key roles in oncogenesis and remain
important drug targets, but are not associated with shorter survival times243. Thus, identifying
novel ways of assessing heterogeneity and EMT parameters within a patient tumor through the
use of combinatorial predictive biomarkers could prove useful in the clinical assessment these
features and inform therapeutic decision-making.
3.5 Methods
Cell culture
The human derived SUM149PT cell line was obtained from the Weinberg lab, who in turn
acquired it from Dr. Stephen P. Ethier (Michigan). All derivative cell lines were maintained
in F12 medium (Gibco #11765-054) supplemented with 5% fetal bovine serum (FBS) (Gibco
#10438-026), insulin (1 mg/ml; Gibco #12585-014), and hydrocortisone (1 mg/ml; Sigma #
H4001) and 5% Penicillin-Streptomycin (Corning #10-002-cl). All cell lines were incubated at
37ºC with 5% CO2-air atmosphere with constant humidity. Cells were passaged with 0.25%
Trypsin (Corning 25-053-Cl); passage number was kept on all cell lines, and cultures were
discarded past a total of twenty passages to maintain their respective EMT phenotypes. 293T
cell line was maintained in DMEM + 10% fetal bovine serum (Gibco #10438-026) + 5%
Penicillin-Streptomycin (Corning #10-002-cl).
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Lentiviral Vectors
Lentivirus was made with 293T cells plated at 60% confluency in 10cm tissue culture treated
plates and transfected using X-tremeGENE HP DNA Transfection Reagent (Sigma #
6365779001) with lentiviral vectors, psPAX2 (1.5ug, Addgene #12260), pCMV-VSV-G (1.5ug,
Addgene #8454), and pcDNA3-eGFP (0.5ug, Addgene #13031) plus the lentiviral vector of
interest (3ug). Supernatant collected at 48 and 72 hours post-transfection, concentrated using
Lenti-X concentrator (TakaraBio #631232), and titer determined with Lenti-X GoStix (TakaraBio
#631243).
Cell line Generation
Parental cell line SUM149PT was maintained in standard media. To generate single cell clones,
fluorescence assisted cell sorting (FACS) was performed on SUM149PT with the FACSAria III
Cell Sorter. Cells were stained with CD44-PeCy7 1:100 (Biolegend 103030), CD104-APC 1:200
(Invitrogen #50-1049-82), or Epcam-BV510 1:100 (BioLegend #324235) for 30 minutes on ice
before addition of DAPI 1:1000 (SigmaAldrich 10236276001, 10mM stock). Gating and
compensation were done on single stained controls, and cells were sorted into collection tubes
and immediately plated at a dilution of 0.5 cells per well into a 96-well plate. Single cell clones
were then expanded and assessed for EMT characteristics.
ZsGreen expressing cells
All SUM149PT clones and parental line were infected with high titer pHIV-Luc-ZsGreen
(Addgene #39196) virus so as to generate ZsGreen and Luciferase expressing tumor cells for
metastasis tracking in mouse. 6x105 cells were infected in 6-well plates with 125uL of high titer
virus in standard media with 5ug/mL Polybrene (Sigma-Aldrich). Media was changed after 24
hours, and cells allowed to expand for 48 hours before sorting for ZsGreen positive population
on the FACSAria III Cell Sorter, as above.
Flow Cytometry
Flow experiments were performed in the same manner as above, on a 10-color Gallios FACS
cytometer (Beckman Coulter). Compensation, file analysis, and plot generation was conducted
using FlowJo (BD).
RT-qPCR
RNA was harvested from 6-well plates of cells at confluency, extracted using the Qiagen
Rneasy plus kit (Qiagen 74034) and quantified using a NanoDrop (Thermo Fisher Scientific –
ND-2000-US-CAN). Reverse transcriptase PCR (AppliedBiosystems #4368814) was performed

- 69 -

to generate cDNA and Power SYBR green PCR mastermix (Applied Biosystems) was used for
qPCR.
Western Blot
For western blot, lysates were collected on-plate with 1x RIPA buffer (EMD Millipore #20-188)
with protease and phosphatase inhibitors (ThermoScientific #1861280). Lysates were sonicated
and cleared before quantification with a Bradford Protein assay (BioRad) and loaded at 50ug
per lane and run on a NuPage Bis-Tris gel (ThermoFisher) and transferred to nitrocellulose
membrane with the iBlot semi-dry transfer system (ThermoFisher) and blocked in 5% milk in
TBST before staining with Fibronectin (BD #610078, 1:10,000), ZEB1 (LSBio ## 1:2000), Ecadherin (BD #610182, 1:1000), Vimentin (Cell Signaling Technology; CST #5741, 1:2000),
RUNX1 (CST #4336, 1:2000), RUNX2 (CST #12556, 1:2000), RUNX3 (CST #9647, 1:2000),
CBFb (Abcam ab33516, 1:2000), Snail (CST #3879, 1:1000), Twist1/2 (abcam ab50887, 1:50),
and CoxIV (CST #11967, 1:2000) overnight in 5% milk in TBST. LiCor secondary antibodies,
IRDye goat anti-rabbit and goat anti-mouse, 800CW (LiCor #925-32219) and 680RD (LiCor
#925-68076), applied at 1:10,000 for 1 hour RT in 5% milk in TBST before imaging on the LiCor
Oddessey CLx Digital Imager.
Transwell Assay
Transwell assays were conducted using Costar Transwell plates (#3422 8.0 µm) in triplicate.
For migration assays, 2.5E5 cells were added to the top of each well in 10% complete medium,
with 100% complete medium beneath the transwell. Cells were incubated for 16-18 hours at
37ºC. Media was aspirated and cells were permeabilized with 100% methanol for 5 minutes RT
followed by staining with crystal violet (0.5% crystal violet in 20% methanol). Transwells were
imaged on a Nikon Eclipse TS100 and migrated cells were counted using ImageJ. Invasion
assays were conducted as above on plates that were coated with 100uL of 5% Matrigel to the
top of each transwell and allowed to set at 37ºC for two hours before seeding.
RUNX2 and CBFb knockout
CRISPR-Cas9 mediated knockout was achieved through lentiviral infection of lentiCRISPR V2
(addgene #52961) containing guides targeting RUNX2, CBFb, or a LacZ non-targeting control
guide (table below, sequence aquired from Sigma Presesign CRISPR gRNA). Constructs were
confirmed by Sanger sequencing and used as vectors in lentivirus production as stated above.
Cells were infected with 1/8th lentiviral product from a 10cm plate in 6-well plates. Media was
changed after 24 hours and puromycin selection (2ug/mL) was applied at 48 hours until stable
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cell lines generated. Cell lines were checked for knockout by western blot, and LacZ #1, RUNX2
#2 and CBFb #2 were used for further analysis based on level of knockout.
Cell lines used for western blotting as described above, and orthotopic injection into the
mammary fatpad of NSG mice, as described below.
Cell Imaging
Bright Field
Images were taken on a Nikon Eclipse TS100 under 20x magnification to determine cell
morphology
ImmunoFluorescence
Cells were grown to 60% confluency in chamber slides (Falcon 354118) with standard media.
Cells were fixed and permeabilized prior to staining with primary antibody (Vimentin CST #
1:100 and E-cadherin BD number 1:100) overnight followed by secondary (anti-rabbit
ThermoFisher #31466 1:10000, anti-mouse ThermoFisher #31431 1:10000) for one hour. Slides
were washed and mounted using ProLong Diamond (Invitrogen P36961) before imaging on
Zeiss LSM 800 with Airyscan (63X)
In Vivo Studies
Cell lines were resuspended in 30% Matrigel (VWR 47743-706) and injected in limiting dilutions
(250k, 25k, and 2.5k cells per flank) orthotopically into the inguinal mammary fat pat (no. 4) of
NOD-scid IL2Rgnull (Stock No: 005557; Jackson Laboratory). Tumor growth was monitored
weekly and tumor volume was measured along 3 axes with calipers (VWR 62379-531). Tumors
and lungs were harvested at time of tumor burden (total tumor volume of 2cm3) and fixed
overnight with 10% neutral buffered formalin. Tumor growth curves and survival statistically
analyzed using TumGrowth219. Tumor initiating potential calculated with Extreme Limiting
Dilution Analysis (ELDA)244.
Late metastasis models were obtained through primary tumor resection at 1cm3. Mice were
allowed to recover and lungs were harvested at 2.5 months post-surgery. This interval was
determined by noticeable recurrence at the ipsilateral site and deteriorating health in the mice.
Tumor and Lung staining
Tumors and lungs were extracted at time of tumor burden (total tumor volume of 2cm3) and
fixed overnight with 10% neutral buffered formalin. All samples were then processed and
stained for Hematoxylin & Eosin (H&E) by the Dartmouth Hitchcock Pathology Shared
Resource. Lungs bearing ZsGreen positive EMT clones were counted by eye on Nikon Eclipse
TS100 and select images taken at 4x magnification.
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Metastasis counting
H&E stained lung slides were scanned on a PerkinElmer Vectra3 slide scanner at 10x and
counted by eye for micro (> 10 adjacent cells) and macro (10+ adjacent cells) metastatic
tumors.
Whole Exome Sequecing
Whole Exome sequencing and subsequent SNP and INDEL alignment and discovery was
performed by BGISeq on all EMT clones. They obtained 9,242.46 Mb raw bases. After removing
low-quality reads we obtained averagely 91,977,846 clean reads (9,197.79 Mb). The clean
reads of each sample had high Q20 and Q30, which showed high sequencing quality. The
average GC content was 50.63%. Reads were aligned with Burrows-Wheeler Aligner (BWA).
The HaploTypeCaller of GATK(v3.6) was used to call and identified 190,503 SNPs and 33,385
InDels between all samples. SNPs and InDels for each clone were tested against the
consensus set for clone E to determine possible genetic mutations with a Fishers Exact Test
and plotted as Odds Ratios.
TCGA Survival Analysis
The results shown here are in whole based upon data generated by the TCGA Research
Network: https://www.cancer.gov/tcga using the TCGA-BRCA cohort of patient samples. CBFb
raw counts were normalized using variance stabilizing transformation (VST) and subjects were
stratified into high vs low expression groups based on 50th percentile CBFb
(ENSG00000067955). Expression was modelled as a continuous variable in cox proportional
hazards model adjusting for age, stage (low vs high), and molecular subtype (PAM50).
RNA-seq data processing
RNA was collected using Qiagen RNeasy plus kit (Qiagen 74034) and quantified using a
NanoDrop (Thermo Fisher Scientific - ND-2000-US-CAN). Library preparation performed with
the Kapa mRNA HyperPrep kit.
Quality of raw single-end RNA-seq data was confirmed using FastQC245 (v0.11.8) before read
trimming of polyA sequences and low quality bases using Cutadapt246 (v2.4). Reads were
aligned to human genome hg38 using STAR247 (v 2.7.2b) with parameters “--outSAMattributes
NH HI AS NM MD --outFilterMultimapNmax 10 --outFilterMismatchNmax 999 -outFilterMismatchNoverReadLmax 0.04 --alignIntronMin 20 --alignIntronMax 1000000 -alignMatesGapMax 1000000 --alignSJoverhangMin 8 --alignSJDBoverhangMin 1”. Quality of
alignments was assessed using CollectRNASeqMetrics (Picard Tools248) and duplicate reads
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were identified (but retained) with MarkDuplicates (Picard Tools248). Gene-level abundance
estimates were generated using RSEM249 (v1.3.2) using the rsem-calculate-expression
command with the parameters “--strandedness reverse --fragment-length-mean 313 --fragmentlength-sd 91”.
Downstream RNA-seq data analysis
Gene-level abundance estimates generated with RSEM were imported into R and analyzed
using R-package DESeq2250. Tp perform exploratory analysis of global transcriptional profiles,
abundance were transformed using the regularized logarithm approach250 implemented in Rpackage DESeq2, and the top 500 most variable genes across all clones were supplied to the
prcomp() command in R to perform principal components analysis (PCA). The 500 most
variable genes were also used to perform Unsupervised hierarchical clustering with the Rpackage ComplexHeatmap. Differential expression analysis was performed on the raw genelevel abundance estimates assuming a negative binomial distribution, with clone E used as the
reference group in all comparisons. Gene-wise dispersion estimates were reviewed in all
analyses to confirm the selected model was an appropriate fit for the data. Genes with a
Benjamini-Hochberg adjusted P-value < 0.05 (Wald-test) were considered statistically
significant.
Gene Set Enrichment Analysis (GSEA) was done on differential gene lists for each clone
relative to clone E using the clusterProfiler32 to determine overlaps with the Hallmark gene sets
at a threshold of 0.05.
ATAC-seq data processing
Tagmented DNA and library prep for ATAC-sequencing was performed according to the
protocol detailed in Buenrostro et. al. 2015222
Prior to analysis, quality of raw DNA sequences (in FASTQ format) was confirmed using
FastQC245 (v0.11.8). ATAC-seq data was then processed using the publicly available ENCODE
ATAC-seq pipeline (https://www.encodeproject.org/pipelines/ENCPL792NWO/), and relevant
commands and options used are described in detail below. Illumina adapter and transposase
sequences were trimmed using Cutadapt246 (v1.9.1) with parameters “--minimum-length 5 -e
0.1”. Trimmed reads were then aligned to human genome hg38 using Bowtie2251 (v2.2.6) in “-local” mode with parameters “-X 2000 -k 2”. Duplicate reads were identified using
MarkDuplicates (Picard Tools248) and filtered from final alignments, in addition to unmapped
reads and reads aligning to mitochondrial DNA, retaining only alignments formed by properly
paired reads. For multi-mapping reads, one paired-end alignment was randomly selected as the
primary alignment while the remaining alignments were discarded. Alignments (in BAM format)
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were converted to tagAlign files and shifted +4 bp and -5 bp on the + and – strands,
respectively, to account for insertion of adapter sequences by Tn5 transposase. Peaks were
called for each replicate using the MACS2252 (v2.1.1) callpeak command with parameters “--shift
-75 --extsize 150 --nomodel --keep-dup all --call-summits -p 1.0E-10” and filtered against the
ENCODE hg38 blacklist. The Irreproducible Discovery Rate (IDR) method was used to identify a
set of reproducible peaks across biological replicates using an IDR threshold of 0.05. For
visualization purposes, position-shifted (to account for Tn5 insertion) BAM files for biological
replicates were merged MergeSamFiles (Picard Tools248) and used to generate counts per
million (CPM)-normalized signal-tracks (in BigWig format) via the deepTools253 (v3.4.3)
bamCoverage command with parameters “--binSize 5 --normalizeUsing CPM -effectiveGenomeSize 2913022398 --ignoreForNormalization chrX”. Heatmaps of normalized
Tn5 insertions in peak regions or specific regions were generated using deepTools commands
computeMatrix and plotHeatmap.
Several metrics were used to confirm ATAC-seq data quality. To confirm sequencing libraries
were of sufficient complexity, three specific quality control metrics were evaluated: nonredundant fraction (NRF, number of uniquely mapping reads / total read number), PCR
bottlenecking coefficient 1 (PBC1, number of genomic positions with at least 1 read mapped /
number of distinct genomics position to which a read maps uniquely), and PCR bottlenecking
coefficient 2 (PBC2, number of locations where one read maps uniquely / number of genomic
regions where two reads map uniquely). Fragment length distributions were generated and
reviewed in R using the “Rsamtools” package. The fraction of reads in nucleosome-free regions
(NFRs) was calculated to confirm a sufficient fraction of reads were located in NFRs. Fraction of
reads in peak regions (FRiP score) was calculated to assess the quality of the final IDR peak
set. Enrichment of accessibility over transcriptional start sites (TSSs), calculated as the
maximum number of normalized Tn5 insertions across a +/- 2kb region flanking hg38 TSS
regions, was used to was to confirm data quality in a peak agnostic fashion.
Downstream ATAC-seq data analysis
Basic peak annotation was performed using the annotatePeak() function from the ChIPseeker254
package, using a range of +/- 3kb to define promoter-associated regions. R-package
TxDb.Hsapiens.UCSC.hg38.knownGene was used to define gene models and coordinates of
genomic features. To create a set of consensus peaks, the IDR peak sets for each sample
groups were merged using the GenomicRanges R-package. Tn5 insertions occurring in each
peak of the consensus peak set were counted from position-shifted BAM files using the
featureCounts() function (from the Rsubread package) with options “isPairedEnd=TRUE,
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countMultiMappingReads=FALSE”. To perform exploratory analyses of global chromatin
accessibility profiles, raw counts were transformed using the regularized logarithm approach250
implemented in R-package DESeq2. Principal components analysis (PCA) was performed on
the 3000 most variable consensus peak regions using the prcomp() function in R. The most
variable peaks were defined as those with the greatest standard deviation across all samples.
Unsupervised hierarchical clustering was performed with the ComplexHeatmap R-package, also
using the 3000 most variable consensus peaks. Differential accessibility analysis of the
consensus peak was also performed using the DESeq2 R-package, modelling raw counts using
a negative binomial distribution, with clone E used as the reference group in all comparisons.
Peaks with a Benjamini-Hochberg corrected P-value < 0.05 (Wald-test) were considered
statistically significant.
Enrichment of TFBS in clone-specific peak sets
To identify potential TFs responsible for mediating clone-specific phenotypes, we tested the
differentially accessible peaks between clone E and each clone for over-representation of TF
binding site motifs. We first restricted each peak set to regions that demonstrated statistically
significant increases in chromatin accessibility compared to clone E (see description of
differential accessibility analyses above) and scanned these peaks for TF motif occurrences
using R-package motifmatchr223. Position frequency matrices for human TF motifs used as input
to motifmatchr were downloaded from the JASPAR database255 using R-packages
JASPAR2018 and TFBSTools256. Over-represented TF motifs in each peak set were identified
through hypergeometric testing using the R function phyper(), with all peaks identified in that
clone used as the background set. TF motifs with a Bonferroni corrected hypergeometric Pvalue <0.05 were deemed as over-represented. To identify potential groups of coordinately
regulated TFs across the respective clones, -log10-transformed P-values from hypergeometric
testing were subjected to hierarchical clustering and visualized using R-package pheatmap. To
prevent extreme motif enrichments from dominating the heatmap scale, -log10-transformed Pvalues were capped at a maximum value of 20 (highlighted with an asterisk).
Differential TF activity analyses
Differential TF activity between single-cell derived clones, as well as TF mode of action (i.e.
activator, repressor) was estimated using diffTF228. Briefly, when used with ATAC-seq data,
diffTF computes the fold change in chromatin accessibility between two conditions at each
binding site of a given TF, and the distribution of fold changes is compared to a set of
background fold-change values to assess statistical significance of differences in TF activity
between the conditions. DiffTF was used in conjunction with matched RNA-seq (classification
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mode) to classify each TF into one of the following modes of action (activator, repressor, notexpressed, undetermined) through correlation of TF expression levels with target site
accessibility. DiffTF was used with options “pairedEnd” and “RNASeqIntegration” set to ‘true”,
with all remaining options using default settings. In-silico predicted binding sites based on the
HOCOMOCO v11 database257 and PWMScan258 for hg38 across 768 human TFs was used to
define the atlas of TFBS for diffTF analyses. To concentrate on the TFs with the most
confidently estimated TF activity scores (weighted_meanDifference), we restricted our
downstream analysis to TFs that achieved an adjusted P-value of 1E-15. To identify modules of
cooperatively regulated TFs, unsupervised hierarchical clustering was performed on the diffTF
activity scores using R-package ComplexHeatmap.
Multiplexed TSA staining
Tumors were selected from each EMT clone at approximately 1cm3 and stained with (in order)
Snail (CST #3895, 1:400), KRT8 (Invitrogen PA5-29607, 1:300), KRT14 (Invitrogen MA5-11599,
1:1000), Vimentin (CST #5741, 1:500), E-cadherin (BD #610182, 1:500), and ZEB1 (Invitrogen
PA5-82982, 1:1000). Antibody optimization and multiplexed staining was done according to
PerkinElmer OPAL Assay Development Guide (August 2017) and previous literature210,259.
Briefly, slides were baked to remove paraffin wax, and then sequentially washed with Xylene,
rehydrated with decreasing concentrations of ethanol, and finally ddH20 before blocking. Then
slides were incubated with primary antibody then secondary antibodies for 30 minutes at RT.
Following washes, the selected OPAL fluorophore was applied to slides for precisely 6 minutes
at RT in the dark, washed off, and slides microwaved at 20% power for 15 minutes to affix
OPAL to target regions and remove primary and second antibody (Table 2). Slides were
blocked again and staining process repeated for each marker, and finally spectral DAPI
(PerkinElmer, 2 drops per mL) before mounting on coverslips with ProLong Diamond (Invitrogen
P36961).
Image Analysis
Whole slide scans were captured at 10x with the PerkinElmer Vectra3 Slide Scanner and ~50
regions of interest (ROIs) per tumor chosen manually with PhenoChart (PerkinElmer). ROIs
were imaged at 20x resolution and imported into InForm analysis software (PerkinElmer).
Spectral unmixing single-stains and background fluorescence slides were generated from the
Parental tumor according to the OPAL Assay Development Guide. ROIs were spectrally
unmixed and assigned colors and exported as composite images (Figure 12A). Tissue
(Trainable to 98% accuracy) and cell segmentation were performed (Nuclear compartment –
DAPI, Cytoplasm – Vimentin & KRT8, Membrane – E-cadherin) and cells were phenotyped
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based on expression of one or multiple markers (E-cadherin only, KRT8/14 & E-cadherin, KRT8
and/or KRT14, Triple positive (KRT8+E-cadherin+ Vimentin), KRT8/14 and Vimentin, Snail only,
Vimentin only, and Vimentin+ZEB1) and validated by marker distribution (Figure 15A&B). Entire
Cell Mean Fluorescent units extracted for each marker and normalized as a percentile of
maximum and minimum fluorescence across all cells in all images.
Heterogeneity and EMT Scores
Approach 1: Heterogeneity scores were generated using penalized logistic regression based on
entropies of mean marker cell expressions to identify markers and cellular compartments
(Nucleus, Cytoplasm, and Membrane) that contributed most to the variability in the ranked
tumor images (Figure 15C). In total 134 entropy-based features extracted, and 13 of them were
selected by Recursive Feature Elimination (RFECV)215 as most relevant. Logistic regression
classified sample heterogeneity into levels mid, low and high. Ground truths were determined
from the rubric: low (one major cell trait with up to one minor trait), mid (two major cell traits with
up to three minor traits), and high (three or more major cell traits present with two or more minor
traits). These were used to train and validate the algorithm using 70% training and 30% test
images (n=409) in a five-fold cross validation.
Approach 2: Nearest Neighbor analysis was conducted with the scikit-learn python package234
using cell phenotypes determined from InForm. Similar feature selection methods were applied
to nearest neighbors, with 26 out of 49 features selected.
Approach 3: A hybrid approach used combined the 134 and 49 features from approach 1 and 2
and selected 18 out of 183 features.
To generate the EMT score, the seven derived phenotypes were weighted from epithelial to
mesenchymal (E-cadherin only -3, KRT8 & E-cadherin -2, KRT14 only-1, Triple positive +1,
Snail only +2, Vimentin only +3, and Vimentin & ZEB1 +4) and applied to a multivariate logistic
regression.
Code is available on Github https://github.com/BMIRDS/cell-heterogeneity-emtscore
Human Patient Tumors
Human patient samples were obtained from the Cooperative Human Tissue Network (CHTN)
CPD Breast Cancer Stage III Prognostic Tissue Microarray. Details on this tissue microarray
can be found at https://www.chtn.org/. TMAs were stained as detailed above and unmixed as
described. After QC, 124 sample cores were used for further analysis including phenotyping, as
well as Heterogeneity and EMT score calculation, both described above. Hazard ratios were
calculated with a Multivariate Cox Proportional Hazard model, adjusting for patient age and
tumor hormone status (HR+ or HR-).
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CBFb staining was conducted on sequential CHTN TMAs, above, by immunohistochemical
methods (Abcam ab33516 1:2000). Following staining, TMAs were scored by a licensed
pathologist and marked as negative, weak, moderate, or strong for nuclear and/or cytoplasmic
staining, as well as percentage of cells per core. H scores, such as those used to define ER
expression237, were calculated using the strength of expression (negative = 0, weak = 1,
moderate = 2, strong = 3) multiplied by percent positively stained cells (upper estimate). Hazard
ratios calculated as above.
Survival Analysis
Survival analysis was performed on patient data gathered from the Cooperative Human Tissue
Network. Overall Survival was used to plot Kaplan-Meier and cox proportional hazard models
adjusting for patient age and patient subtype (HR+ or HR-). HR status was determined from ER
and PR score (Negative or Positive) based on ASCO CAP Guidelines for ER and PR

Scoring.
Chapter 5. Concluding Remarks And Future Directions
Cancer, despite its ubiquity and the extensive and concerted efforts of research scientists in the
last 100 years, remains a deadly disease that affects millions every year. This is due in large
part to the variety of diseases under the umbrella of cancer. However, many solid cancer types
share features that tie them, rooted in repurposing of developmental cellular programs to
promote proliferation, motility, and plasticity. The Epithelial-to-Mesenchymal transition (EMT) is
one such program, activated in many solid tumors, and is correlated with increased mortality
and metastasis. The networks that regulate these transition states are complex, but the
progression of EMT in cancer follows very similar trajectories as in normal cells, particularly in
wound healing.
This is due to a complex network of extracellular signaling and transcriptional regulation
that promotes morphological changes within individual and groups of cells to promote cell
motility, invasion, and cellular plasticity. In normal development, this serves to aid in
gastrulation, neural crest migration, and wound healing. However, these traits that confer
plasticity are excellent means to promote disease progression and evasion of therapies in
cancer. Particularly in breast cancer, EMT is a key contributor to heterogeneity, chemoresistance, and metastasis, with the intermediate or hybrid EMT state playing a critical role due
to its increased tumor-initiating potential. Although recently identified, this intermediate state has
opened up a new doorway to understanding the impact of EMT on tumor progression as it
shares both the proliferative and cell-adhesion characteristics of the epithelial cell state, with the
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motility and invasive traits of the mesenchymal state. This combination promotes a robust and
pliant cell type that adapts to the environmental pressures of the metastatic cascade.
Although the regulatory pathways controlling EMT have been well identified and the
drivers of EMT clearly delineated, this information has nonetheless proven relatively fruitless
both as actionable targets in preventing or regulating EMT in a disease context as well as
serving as biomarkers in patient prognosis. This unfortunately has left a gap between the wealth
of understanding surrounding EMT and the actual utility of this knowledge in patient care and
disease mitigation. This is due, in part, to inaccurate and/or inconsistent models between cancer
types and studies, not to mention the transient nature of EMT, which makes it hard to capture
and track. Efforts to understand EMT and E-M Plasticity (EMP) have generally been solely
focused on one or another aspect of the program’s roles in cancer. However, as with many
developmental programs, the effects are widespread and nuanced, working within a framework
to affect many aspects of cellular behavior both singularly and collectively.
Therefore, we approached this question of the role of EMT in breast cancer both
singularly and collectively, by first inspecting single cell states of the EMT spectrum found within
a cell line and comparing them back to the heterogeneous parental line, and then secondly
viewing the whole EMT composition of a tumor. From this we validated the presence of multiple
unique intermediate states that maintained their relative states distinct from one another in
culture and have different migratory abilities in vitro, echoed in qualitative differences in
metastatic abilities in vivo. This suggests that even within the intermediate or hybrid EMT state,
there are differences in metastatic fitness. However, by a gold standard test of stemness, a
limiting dilution assay, these single cell intermediate clones all performed equally well,
suggesting that broad stroke tests may not be able to delineate the nuances of each state. This
is further evident through unique gene sets that are identified in only one or another of the
intermediates, although gene set enrichment analysis had limited success in tying these genes
to common regulatory pathways in the unique gene sets.
Previously identified drivers of EMT, such as Snail, ZEB1, Twist, and others, which have
been well studied, have ultimately proven ineffective as single biomarkers in a clinical setting.
This is perhaps due to the nature of their expression patterns; several EMT TFs are also
expressed in fibroblasts and other mesenchymal cell types in the tumor microenvironment.
Some factors such as ZEB1 are strong drivers of EMT, resulting in complete mesenchymal
transition upon continuous expression or activation in a cell, however, this highly mesenchymal
state is not the disease propagating stage of this transition, as we and others have found.
Rather, the intermediate state, which is the most stem-like, tumor initiating, and metastatic, is
not captured by cells that highly express factors such as ZEB1. In contrast, the use of multiple
markers, especially epithelial and mesenchymal markers in combination, provides a more
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accurate means of identifying cells that reside in an intermediate state. As observed in our
SUM149 system, intermediate states express a higher proportion of cells that co-express
epithelial and mesenchymal markers, compared to the more extreme states.
A multiomics approach has proven more fruitful in identifying regulatory transcription
factors of the intermediate state, such as TFAP2A/B/C and the CBFb-RUNX family, with the
latter being validated by functional assays in our system. These are likely excellent candidates
as both families have broad regulatory functions in developmental processes such as neural
crest migration and wound healing, and have been identified in other screens for EMT relatedgenes. Both CBFb and RUNX2, in particular, have been implicated in breast and lung cancer
metastasis, but the role and mechanism behind this remains unclear. Here, we found that CBFb
is critical to metastasis by maintaining the plasticity and stability of multiple intermediate states,
affecting only the metastatic ability of cells but not their ability to form primary tumors in vivo. We
further found that this decrease in metastatic ability was due to an overall more epithelial tumor
state with decreased tumor heterogeneity. This implies a multifaceted role for CBFb, stemming
from stabilization of the intermediate EMT state(s) that promote tumor heterogeneity and the
metastatic cascade.
This role of CBFb in the intermediate EMT brings in forward a new potential biomarker.
Conversely, CBFb itself, although linked with the intermediate state, has no statistical power in
predicting patient outcome, both in an online database of breast cancer patient gene expression
profiles, as well as a large cohort of patient tumor samples stained for CBFb. Indeed, other
canonical EMT transcription factors mentioned above also have proven inefficient at predicting
patient survival. This makes it challenging for EMT to be used as a prognostic and diagnostic
tool to be adopted into a pathology protocol. In contrast, other predictive markers such as ER,
PR, BRCA1, HER2, and others, have strong links to disease outcome in patients, allowing for
their use as easy screening biomarkers. The lack of predictive biomarkers should not, in itself,
discredit the utility of EMT as a predictive tool, but it should instead be viewed through a
different lens. In keeping with the importance of the intermediate state(s) in a metastasispromoting tumor environment, we endeavored to develop a means of assessing intermediate
states and tumor heterogeneity in patients by immunostaining for a panel of six EMT-related
proteins to delineate the spectrum of cell states in a tumor, thus focusing on EMT in breast
cancer collectively. We found through the SUM149PT model system that high heterogeneity
was associated with intermediate state-derived tumors, which displayed high tumor stemness,
increased growth and metastasis, and resulting decreased mortality in the mice bearing them.
This model may not adequately represent a real-world scenario; patient tumors are rarely of a
single origin and the originating cell state of those transformed cells is unknown. However,
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through this clonal model we learned that cell phenotypes with high stemness (i.e. the
intermediate clones) produced tumors with high diversity of cellular phenotypes and an
increased potential for metastasis. When applied to a cohort of patient breast cancer tumor
samples, we found that not only were the same cell phenotypes identified in all patients as in
the SUM149PT model, but that scores for E-M heterogeneity and overall EMT score first
developed from the model system were able to accurately predict patient overall survival in the
breast cancer cohort. As with our model, an overall intermediate EMT score (i.e. tumors with
predominantly intermediate EMT phenotypes) and a high E-M heterogeneity score (i.e. a high
diversity of cell states) were both associated with poorer overall survival in both hormone
negative (ER-/PR-) and hormone positive patient samples. This multiplexed immunostaining
panel and analysis was designed with high throughput in mind, so that it can be applied in a
pathology core alongside other routine staining for patient diagnostics.
Future directions for this panel include more broadscale testing on a variety of cancer
types to test applicability across solid tumors, as well as more in depth testing in breast cancer.
We are optimistic that this is an applicable and useful tool that can one day be readily applied in
a clinical setting alongside current methods to leverage our understanding of EMT on cancer
and metastasis and more effectively assess patient stage and metastatic potential. In parallel,
CBFb remains a promising molecular target, due to its stabilizing role in the intermediate EMT
state, as well as the “druggability” of the runt interaction domain between CBFb and co-factors
RUNX1/2/3. Destabilization of this interaction domain, either by disruption with a small molecule
or antibody-targeted downregulation of CBFb may present a viable way of effectively pursuing
and inhibiting this metastasis-promoting cellular phenotype. Future clinical trials may pursue
routine screening of patient samples for high E-M heterogeneity and overall intermediate
phenotype via the multiplexed immunostaining approach described above, and design a
targeted therapy against CBFb to minimize risk of metastasis in those patients.
Multiplexed immunostaining provided a means of assessing EMT state of, not just the
primary mouse tumor, but the lung metastases as well. Contrary to current dogma, metastases
in the mouse lungs seeded by all clonally derived EMT tumors were predominantly
mesenchymal in nature, expressing vimentin, cytokeratins, and ZEB1, and notably lacking
expression of E-cadherin. However, it is unclear whether this is due to transition to a more
mesenchymal-like state at the lung site or whether the tumor cells in circulation are
mesenchymal when they reach the secondary site. Previous literature suggests that
intermediate circulating tumor cells or clusters of cells are more advantageous for promoting
metastasis. This fits with our understanding that more intermediate state tumors, i.e. those both
derived from intermediate clones and those possessing more intermediate-associated cell
phenotypes, are more metastatic. Therefore, it is plausible that environmental signaling in the
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lung promotes a more mesenchymal cell type. Future directions may include sampling
circulating tumor cells and clusters from this SUM149PT orthotopic mouse model to
immunostain with the same panel of EMT markers and determine the EMT composition of tumor
cells in circulation. This same immunostaining can also be applied to the lungs and secondary
sites of other orthotopic or mouse models of breast cancer such as MMTV-PyMT to determine if
metastatic cells in the lungs of these models are equally lacking in E-cadherin and other
epithelial cell phenotypes.
Tumors develop over time and environmental pressure. This process can be viewed
through the lens of evolution to understand how different cellular phenotypes and genotypes
contribute to the overall formation of cancer as well as the intra-tumoral heterogeneity that
contributes to therapy resistance. Future directions may consider the consequences that
epithelial-mesenchymal plasticity (EMP), in particular that of the intermediate state, have on the
evolution of tumors and generation of tumor heterogeneity. We found through this work that
tumors originating from intermediate clonal populations resulted in tumors with high levels of EM heterogeneity, higher even than those generated from the already heterogeneous parental
cell line SUM149PT. However, these tumors were assessed at endpoint, and nuances of their
formation and evolution in the mouse were not gleaned. Future studies may benefit from a
snapshot glance at the formation of tumor heterogeneity as the tumor progresses, either at
different sizes or timepoints throughout tumor development.
This work has used a multidisciplinary approach to study the effects and drivers of EMT
in a single model of breast cancer. While this model cannot encompass the breadth of cell types
and conditions present in patients, it provides the benefit of a single background upon which to
test and assess many aspects of the epithelial-to-mesenchymal transition on cancer formation,
tumor progression, and metastasis. Along the way, we have validated these findings in large
datasets, other cell line models, and previous reports to contextualize this study and provide
perspective for these findings in the larger milieu of EMT work in hopes to shed light on the
contribution of EMT in breast cancer.
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